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1. Introduction 
1.1 Phosphoinositide 3-kinases (PI3Ks) 
Phosphoinositide 3-kinases (PI3Ks) are a group of enzymes that catalyse the transfer of 
γ phosphate group of ATP to the D3-position of inositol ring of phospotidylinositols 
(PtdIns), PtdIns-4-phosphate (PtdIns4P) and PtdIns-4,5-biphosphate (PtdIns(4,5)P2). 
PI3Ks can be activated by stimulation of cell surface receptors. The D-3 phosphorylated 
lipids produced by activated PI3Ks bind to PH domain containing signaling mediators 
that coordinate various signaling events regulating cellular processes like gene 
expression, protein synthesis, cell growth, metabolism, cytoskeletal rearrangements and 
vesicle trafficking. The termination of PI3K signaling involves degradation of 
phosphorylated lipids by lipid phosphatases. The Src-homology (SH2)-domain 
containing inositol 5-phosphatase type 2 (SHIP2) or inositol polyphosphate-5-
phosphatase E (IPP5E) dephopshorylate PtdIns(3,4,5)P3 at 5’-OH position of the 
inositol ring converting it to PtdIns(3,4)P2. Another lipid phosphatase, such as 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) dephosphorylates 
the PtdIns(3,4,5)P3 at 3-OH position to produce PtdIns(4,5)P2 (Cantley, 2002; Hawkins 
et al., 2006; Vanhaesebroeck et al., 2010). 
Eight different PI3K catalytic subunits have been identified so far in mammals. On the 
basis of structural and functional homology, PI3Ks have been classified into three major 
classes, class I, II and III (Hawkins et al., 2006). 
 
1.2 Class I PI3Ks 
Class I PI3Ks are heterodimeric proteins that contain a catalytic subunit of 110 kDa and 
an associated adapter/regulatory subunits. Four types of closely related catalytic 
subunits and two distinct families of regulatory subunits were reported so far. Based on 
the type of regulatory subunits they bind to class I PI3Ks are subdivided into class IA 
and class IB. The class IA consists of p110α, p10β and p110δ catalytic subunits that 
bind to p50-55/p85 type of regulatory subunits to form tight dimers. Class IB consists of 
a dimer of catalytic subunit p110γ and regulatory subunit either of p101 or p84 (also 
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known as p87
PIKAP
). Basically they phosphorylate PtdIns(4,5)P2 to produce 
PtdIns(3,4,5)P3 in vivo (Hawkins et al., 2006). 
1.2.1 Class IA PI3Ks 
Class IA PI3Ks consists of 3 catalytic isoforms – p110α, p110β and p110δ cloned by 
different groups (Hiles et al., 1992; Hu et al., 1993; Vanhaesebroeck et al., 1997). 
Human cells contain three genes PI3KCA, PI3KCB, PI3KCD that encode the catalytic 
subunits of class IA PI3K enzymes termed PI3Kα, PI3Kβ and PI3Kδ, respectively. The 
isoforms p110α and p110β are expressed ubiquitously whereas p110δ is expressed 
predominantly in leukocytes. They bind to regulatory subunit of p50-85 kDa, which has 
multiple isoforms-p85α, p85β, p55α, p50β and p55γ (Vanhaesebroeck et al., 2010). 
 
1.2.1.1 Structure 
The p110 subunits of class IA PI3Ks have five domains: an N-terminal domain called p-
85 binding domain, also called ABD (adapter binding domain) that binds to regulatory 
subunits of p85 family members, a RAS-binding domain (RBD), a C2 domain that has 
been proposed to bind to cellular membranes, a helical domain of unknown function, 
and a kinase catalytic domain. The structure of the catalytic subunits of class I PI3Ks 
are presented in Fig.1.1 (Vanhaesebroeck et al., 2010). 
 
Fig. 1.1: Domain structure of the catalytic subunits of class I PI3Ks 
(Vanhaesebroeck et al., 2010). 
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Fig. 1.2: Domain structure of the regulatory subunit of the class I PI3Ks 
(Vanhaesebroeck et al., 2010) p87 also called as p84 regulatory subunit was found to 
have two molecular weights (Suire et al., 2005; Voigt et al., 2006). 
 
1.2.1.2 Regulatory subunits 
The regulatory subunits of class IA PI3Ks are collectively referred to as p85 and are 
encoded by three genes in humans called as PI3KR1, PI3KR2 and PI3KR3. PI3KR1 
encodes p85α, p55α and p50α, while PI3KR2 encodes only p85β and PI3KR3 encodes 
only p55γ. The regulatory subunit p85 also contains five domains: an N-terminal SH3 
domain, proline–rich region and BCR homology (BH) (breakpoint cluster region 
homology) domain, and two SH2 domains (the more N-terminal nSH2 and the C-
terminal cSH2) separated by an iSH2 domain or p110-binding domain, which is 10 nm 
– long rigid coil (Wu et al., 2007) which is responsible for binding to the catalytic 
subunit at ABD site. In total, mammals have 5 distinct p85 isoforms potentially giving 
rise to fifteen distinct p85-p110 combinations. The amino acid sequences of p110β and 
p110δ are 55 % identical but they are only 40 % identical to p110α, which is more 
frequently found to be mutated in many cancers. The interactions of ABD and kinase 
domain of p110α are distinct from that of p110β or p110δ and mutations in these 
regions are more frequent (Amzel et al., 2008; Vanhaesebroeck et al., 2010).  
Class IA PI3Ks are activated by receptor tyrosine kinases. Regulatory subunits 
translocate the catalytic p110 subunits to the plasma membrane where their substrate 
PtdIns(4,5)P2 is located. SH2 domains of the p85 regulatory subunits direct the PI3K 
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complexes to phosphorylated Tyr-X-X-Met motifs (where X is an amino acid) on 
protein tyrosine kinases or their substrates (Wymann et al., 2003). Interaction between 
p85 and p110 catalytic subunit regulate their enzymatic activity (Huang et al., 2007; 
Miled et al., 2007). Lipid kinase activity of these enzymes catalyze the phosphorylation 
of the PtdIns(4,5)P2 to produce PtdIns(3,4,5)P3 which then bind to PH domain 
containing effector proteins including Ser/Thr protein kinases (AKT), Tyr protein 
kinase (BTK), adapter proteins like GAB2 and regulators of small GTPases like GAPs 
and GEFs, which mediate large range of cellular processes such as proliferation, 
survival, cytoskelatal remodeling and membrane trafficking. Five distinct p85 isoforms 
were recognized. They can bind non-specifically to any of the catalytic subunits, in vitro 
although their binding preference to distinct p110 catalytic units in vivo needs further 
understanding (Vanhaesebroeck et al., 2010). Genetic inactivation of p85 regulatory 
subunits has differential roles. Genetic deletion of p85α, by deletion of exon 1 of 
PI3KRI, resulted in attenuation of PI3K function downstream of B cell receptor 
(Fruman et al., 1999; Suzuki et al., 1999). Loss of P85α or p85β resulted in increased 
insulin signaling (Ueki et al., 2002). 
 
1.2.2 Class IB PI3K-PI3Kγ  
PI3Kγ was cloned in our laboratory (Stoyanov et al., 1995). It is encoded by PIK3CG 
(Hirsch et al., 2000a). It consists of a dimer of p110γ catalytic subunit and p101 
(Stephens et al., 1997) or p84/87 (Suire et al., 2005; Voigt et al., 2006) regulatory 
subunit. Expression of P110γ has been thought to be limited to leukocytes (Hirsch et al., 
2000b) but recent studies reported its expression not only in white blood cells but also 
in mastocytes (Bohnacker et al., 2009), endothelial cells (Puri et al., 2005), airway 
smooth muscle cells (Jiang et al., 2010), heart (Patrucco et al., 2004), brain (Narita et 
al., 2004) and neuronal cells (Cunha et al., 2010; König et al., 2010). 
 
1.2.2.1 Structure  
The crystal structure of PI3Kγ revealed that it contains defined protein modules starting 
from N terminal, consists of RAS binding domain, lipid binding C2 domain, helical 
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(PI3K homology) domain and the ATP binding kinase domain (Pacold et al., 2000; 
Walker et al., 2000) (Fig. 1.1 & 1.3). 
 
 
Fig. 1.3 The ATP binding site of PI3Kγ enzyme. The structure of the PI3Kγ enzyme catalytic 
subunit consists of a helical domain with ATP binding site, C2 catalytic domain, Ras-binding 
domain, N and C terminal catalytic domain (Walker et al., 2000). 
 
1.2.2.2 Regulatory subunits 
The p110γ catalytic subunit binds to the adapter/regulatory subunits p101 or its 
homolog p84 or p87
PIKAP
 which have distinct sequences (Fig. 1.2). PI3KR5 encodes 
p101 subunit whereas PI3KR6 encodes p84/87 subunits. The nomenclature p84 or p87 
was because the protein was found to have different molecular weights. The regulatory 
subunits bind p110γ upon stimulation of Gi subtype of G-protein coupled receptors 
(GPCRs) to form two types of complexes, namely, p110γ:p84 complex and p110γ:p101 
complex. The non-redundant functions regulatory subunits were reported recently. 
Upon adenosine receptor stimulation binding of p84 to p110γ is required to produce 
PtdIns(3,4,5)P3, phosphorylation of AKT, migration of cells and synergistic adenosine 
enforced degranulation of mast cells. In addition, PtdIns(3,4,5)P3 pools produced by 
p110:p101 complex were rapidly endocytosed to motile microtubule-associated vesicles 
distinct from the PtdIns(3,4,5)P3 pools produced by p84:p110γ complex. Moreover,  
p84:p110γ signaling was essential for full scale degranulation of mast cells as the 
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reconstitution of PI3Kγ null cells with p110γ and p101 was unable to restore this 
function (Bohnacker et al., 2009). 
PI3Kγ is activated by Gi subtype of GPCRs. Its interaction with Gβγ subunits of 
heterotrimeric G-proteins result in activation of MAPK upon stimulation of muscarinic-
m2 receptors was identified in our laboratory(Lopez-Ilasaca et al., 1997). Further, the 
direct interaction between Gβγ subunits and N, C terminal sites of p110γ was reported 
(Leopoldt et al., 1998). Later on, the dual kinase activities of p110γ were deduced, 
indicating that the protein kinase activity was responsible for the activation of MAPK 
whereas lipid kinase activity produces PtdIns(3,4,5)P3 subsequently activating protein 
kinase B (AKT). In their experiments, Bondeva et al., showed that replacing the 
catalytic core of PI3Kγ with that of class II PI3Ks or calss III PI3Ks or FRAP (a 
member of the target of rapamycin family without assigned lipid kinase activity) 
affected the lipid kinase activity as measured by their ability to phosphorylate different 
phosphatidylinositol substrates. Moreover, the ability of these constructs to 
phosphorylate the MAPK was not affected suggesting the protein kinase activity was 
unaltered. Further, they reported that the PI3Kγ dependent phosphorylation of MAPK 
was not affected by mutations in RAS binding site of PI3Kγ (Bondeva et al., 1998). 
 
1.3 Structural similarities of p110α and p110γ 
The Ras binding domain (RBD) of free structure of PI3Kγ has a mobile loop. Residues 
of 255-267 within RBD of p110γ constitute this mobile loop i.e. which are not ordered 
and binding of Ras results in proper ordering of this mobile loop (Pacold et al., 2000). 
In case of p110α this loop is ordered and is in a distinct conformation from that of 
p110γ-RAS structure. Part of this mobile loop in p110α is locked in the ATP binding 
site of the kinase domain of a neighboring molecule in the p110α niSH2 crystal. Pacold 
et al., based on the comparison of structures of free p110γ and p110γ-RAS complex, 
suggested that in a Ras-p110γ complex the C2 domain and kinase domain were spread 
apart due to an allosteric effect. The binding of p85 to p110α has a similar effect. The 
C2 domain of p110α interacts with the iSH2 domain of p85α. One of the residues 
responsible for such interactions is Asn 345 of C2 domain of p110α is situated on a loop 
called CBR1. There is no sequence similarity between CBR1 regions of p110γ and 
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p110α. The CBR1 region of p110γ is incompatible to binding with p85 because it would 
clash with iSH2 domain. This explains why p110γ binding required another regulatory 
subunit p101. Mutations in the helical domain of p110α most commonly seen are at the 
residues E542K, E545K. E545 is conserved in all class IA PI3Ks whereas it is replaced 
by Ala in p110γ. The kinase domains of p110α and p110γ represent the most conserved 
residues in the two proteins. Helix αK12 in p110α and helix kα11 in p110γ, constitute 
one of the most divergent features of the two structures. The His 1047 Arg in helix 
αK12 in p110α undergoes oncogenic mutations. This residue might form a hydrogen 
bond with Leu956. The corresponding residues in p110γ are Arg 1076 and Leu987 
indicating that this region is conserved in both the structures but they did not interact 
with each other as in the case of p110α, which means no oncogenic mutations were 
identified in p110γ. The residues that line the ATP binding pockets of p110α and p110γ 
are highly conserved and have similar three-dimensional structures. The binding of 
wortmannin forms covalent bond with Lys833 and makes hydrogen bonds with Asp964, 
Ile963, Val882 and Ser806 in p110γ. All the five residues are present in p110α but the 
binding of wortmannin to p110α is different. Moreover, the loop between residues 771-
799 in p110α adopts a different conformation than the corresponding loop in p110γ 
(residues 803-811) (Pacold et al., 2000; Amzel et al., 2008). 
 
1.4 G-protein coupled receptors 
G-protein coupled receptors (GPCRs) represent the largest family of cell surface 
molecules involved in signal transmission, accounting for > 2 % of the total genes 
encoded by the human genome.  All GPCRs are essentially composed of seven-
transmembrane α-helices that intertwine in and out of the membrane. Upon stimulation 
by agonists, heterotrimeric intracellular sites containing α, β and γ subunits will be 
exposed and dissociation of GDP bound to Gα subunit and its replacement by GTP 
takes place. This leads to the dissociation of Gα and Gβγ subunits representing a 
functional dimer. Both Gα and Gβγ subunit complexes then stimulate several 
downstream effectors independently (Fig. 1.4) (Dorsam and Gutkind, 2007). GPCRs 
receive external signals from hormones, neurotrnasmitters, chemokines, paracrine and 
autocrine factors and relay them inside the cells via G-proteins initiating several 
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interconnecting signal transduction pathways and effecting many cellular processes like 
transcription, motility, contractility, secretion, cell proliferation, growth and 
differentiation (Neves et al., 2002).  
The α-subunits of G-proteins are divided into four subfamilies: Gαs, Gαi Gα12, and 
Gαq. A single GPCR can bind several Gα proteins. Each G-protein activates several 
downstream effectors. Typically, Gαs stimulates adenylyl cyclase and increases 
intracellular cAMP levels, whereas Gαi inhibits adenylyl cyclase and decreases 
intracellular cAMP levels.  Members of Gαq family bind to and activate phospholipase 
C which cleaves PtdIns(4,5)P2 into diacylglycerol (DAG) and inositol triphosphate 
(IP3) (Fig. 1.4). In addition, β and γ subunits were more diverse, there are 5 β subunits 
(highly similar sequence), 12-14 γ subunits (more diverse). Gβγ subunits function as a 
dimer to activate many signaling molecules including phospholipases, ion channels and 
lipid kinases (Dorsam and Gutkind, 2007), of particular importance to mention, is its 
binding to p110γ and subsequent activation of MAPK (Lopez-Ilasaca et al., 1997). 
 
Fig. 1.4: Signaling via G-protein coupled receptors. Upon agonist stimulation GTP 
attaches to the Gα-subunit which then dissociates itself from Gβγ subunits. Gα and Gβγ 
are functional dimers that can signal independently. Four types of Gα-subunits mediate 
different signaling pathways. GRK, PKA phosphporylate the C-terminus of GPCR 
leading to uncoupling of GPCR from G-protein and termination of GPCR signaling 
(Modified from (Dorsam and Gutkind, 2007)).  
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GPCRs, in general, can couple to more than one type of G-protein. This could happen 
following phosphorylation of the receptor or chronic stimulation with the agonist. β2-
adrenergic receptors (β2-AR)  classically reported to be coupled to Gs type of proteins. 
Agonist stimulation of β2-AR leads to increased adenylyl cyclase activation, rising 
intracellular cAMP levels and associated PKA levels. Daaka et al., reported the 
activation of MAPK following isoproterenol stimulation of HEK293 cells expressing 
β2-AR. Interestingly, H-89 which inhibits PKA could inhibit the isoproterenol induced 
activation of MAPK. The authors indicated that PKA can phosphorylate the β2-AR 
which then switches its coupling to Gi-protein resulting in non-conventional, pertussis 
toxin (PTX) sensitive inhibitory signal propagation via non-receptor tyrosine kinase C-
Src and the G-protein RAS dependent activation of MAPK (Daaka et al., 1997). 
Zamah et al., generated two types of mutant β2-AR with mutations at consensus PKA 
binding site one containing alanine (Ala) substituted for serine (Ser) and another one 
containing Ser substituted with aspartate (Asp). They reported that mutant β2-AR with 
Ala substituted for Ser at consensus PKA sites was able to activate adenylyl cyclase but 
not ERK where as the mutant β2-AR with Ser substituted with Asp was able to activate 
adenylyl cyclase and ERK also. In the latter case, the activation of adenylyl cyclase was 
via a PTX insensitive pathway whereas activation of ERK was abolished by PTX 
suggesting that this mutant receptor was able to couple to Gi proteins. Further 
investigations carried out in completely reconstituted system of wild type or PKA site 
mutant β2-AR, heterotrimeric Gs and Gi protein, indicated that β2-AR with the PKA site 
mutants show reduced phosphorylation by PKA. Moreover, PKA mediated 
phosphorylation of purified wild type β2-AR, in vitro,  leads to reduced binding to Gs 
protein and increased binding to Gi protein upon stimulation with isoproterenol as 
measured by the G-protein activation by its ability to bind [
35S] GTPγS (Zamah et al., 
2002). 
 
1.4.1 µ-Opioid Receptor 
µOR is a GPCR that signal by catalyzing the ligand-dependent nucleotide exchange on 
Gi and Go proteins. They act by inhibiting adenylyl cyclase, inhibiting N-type calcium 
channels and activating G protein-gated inwardly rectifying potassium (GIRK) – type 
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potassium channels (Whistler et al., 1999). Different endogenous peptides act as 
agonists at µOR. They included β-endorphine which is a non-selective agonist whereas 
endomorphin1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin2 (Tyr-Pro-Phe-Phe-NH2) are 
highly selective for µOR (Zadina et al., 1997). External agonists of µOR consists of a 
class of analgesics called opioid analgesics acts predominantly on µOR (along with 
other opioid receptors) to exert their main physiological actions. Morphine, an opioid 
alkaloid, is one of the drugs used to treat moderate to severe pain acts as an agonist at 
µOR. Etonitazine, etorphine, methadone are some of the other opioid analgesics with 
relatively different levels of capabilities to produce analgesia, tolerance development 
and addiction/physical dependence (Martini and Whistler, 2007). Inhibition of adenylyl 
cyclase mediated by morphine or DAMGO (Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol, a 
synthetic peptide, µ-opioid receptor specific agonist) does not require full receptor 
occupancy (Chavkin and Goldstein, 1984; Costa et al., 1992). However, opioid 
mediated activation of inwardly rectifying potassium channel currents requires higher 
agonist occupancy at the receptor (Kovoor et al., 1998). 
µOR is a GPCR that is classically known to bind to Gi proteins causing inhibition of 
adenylyl cyclase upon acute stimulation with agonists. However, chronic agonist 
stimulation of µOR causes super activation of adenylyl cyclase leading to abnormally 
higher cAMP levels. This phenomenon serves as a hallmark of addiction/withdrawal 
syndrome following chronic morphine/opiate treatment (Avidor-Reiss et al., 1996). The 
mechanistic basis of such initial inhibition followed by stimulation might involve signal 
switching from inhibitory type of G-proteins to stimulatory type of G-proteins. Several 
attempts to understand the molecular mechanisms involved in µOR signal switch were 
reported. Zhang et al., reported that association of Src kinase and µOR within the lipid 
raft domains and subsequent phosphorylation of µOR at Tyr336 by Src kinase leads to 
switching of its coupling to a stimulatory Gi2α subunit (Zhang et al., 2009). Chakrabarti 
et al., reported the association of µOR with Gsα protein. In their studies they showed 
that in Chinese hamster ovary (CHO) cells stably expressing µOR, the 
immunoprecipitates obtained with anti-Gsα antibodiy contain µOR 
coimmunoprecipitated with Gsα protein. The authors also reported that acute and 
chronic morphine treatment increased the magnitude of µOR coimmunoprecipitated 
with Gsα (Chakrabarti et al., 2005). Rozenfeld et al., reported that heterodimerization of 
Introduction | 11 
 
 
 
µOR with δOR leads to the switch in signaling with respect to ERK1/2 activation. In 
their studies with CHO cells expressing either µOR alone or µOR and δOR together, 
they demonstrated that stimulation with DAMGO resulted in differential patterns of 
phosphorylation of ERK1/2. CHO cells expressing µOR alone showed a peak 
phosphorylation of ERK at 5 min whereas the CHO cells expressing both µOR and δOR 
together, at high heterodimeriaztion states, showed a first peak at 3 - 5 min and a second 
peak at 15 min. SKNSH cells expressing heterodimers of µOR and δOR endogenously 
also  showed similar behavior. Moreover, the second peak could be blocked by 
knockdown of β-arrestin2 or treating the SKNSH cells with a combination of µOR 
agonist and δOR antagonist suggesting that the effect was indeed due to 
heterodimerization of µOR and δOR. The authors concluded that heterodimerization of 
µOR and δOR leads to a constitutive recruitment of β-arrestin2 to the receptor complex 
regulating the ERK1/2 activation and subsequent signaling (Rozenfeld and Devi, 2007). 
 
1.4.3 Desensitization and tolerance development  
Desensitization is a process wherein sustained stimulation of the GPCR leads to 
diminished receptor responsiveness over time such that the receptor no longer responds 
to the agonist stimulation. Desensitization of GPCRs begins within seconds of agonist 
stimulation and involves phosphorylation of the receptor. Second messenger-regulated 
protein kinases like PKA/PKC phosphorylates the receptor at serine/threonine residues 
within cytoplasmic loops and C-terminal domains. This phosphorylation leads to 
abrogation of further GPCR-G-protein coupling. Phosphorylation of a receptor other 
than that stimulated could also happen, as the receptor phosphorylation is independent 
of agonist occupancy at the receptor, leading to heterologous desensitization. In this 
way receptors for different ligands can be affected simultaneously. Homologous 
desensitization is a two step process involving phosphorylation of the receptor by GRKs 
(GPCR kinases) and subsequent binding of β-arrestins leading to uncoupling of 
receptor–G-protein complex. Agonist occupancy is a prerequisite for homologous 
desensitization and endocytosis of the receptor-β-arrestin complex might occur in many 
cell types (Smith and Luttrell, 2006). 
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Antinonciceptive tolerance development following repeated administration of morphine 
is a peculiar problem that limits the clinical use of such an excellent pain relieving drug. 
Tolerance development to morphine induced analgesia is attributed mainly to cellular 
and molecular adaptations occurring following stimulation of µOR, because morphine 
predominantly acts on this receptor to elicit its analgesic activities. µOR knockout mice 
did not show morphine induced antinonciception, respiratory depression inhibition of 
gastrointestinal transit and addiction (Matthes et al., 1996; Sora et al., 1997; Bohn et al., 
2003). 
Molecular mechanisms involved in development of tolerance are quite complex and 
involves multiple signaling mediators and pathways. In a model of thermal 
antinonciception Bohn et al., showed that β-arrestin-2 knockout mice showed enhanced 
and prolonged antinonciception compared to wild type mice following short term and 
long–term treatment with morphine (Bohn et al., 1999; Bohn et al., 2000). 
Internalization of µOR following acute agonist stimulation leading to removal of µOR 
from the cell surface (plasma membrane) and desensitization (uncoupling of receptor 
from G-protein) following chronic agonist stimulation might lead to tolerance 
development (Hsu and Wong, 2000). At signal transduction level, the mechanisms that 
contribute to the development of tolerance reported include phospolipase C mediated 
activation of NMDA (N-methyl-D-aspartate) receptor and nitric oxide synthase (NOS) 
leading to antiopioid effects (Hsu and Wong, 2000). Further, involvement of PKC in 
desensitization of µOR also was reported (Bailey et al., 2009).  
µOR presents a peculiar phenomenon that it exhibits different grades of internalization 
and desensitization following stimulation with different agonists. For example Schulz et 
al., showed that in µOR expressing HEK293 cells, DAMGO induces rapid and robust 
phosphorylation and internalization of µOR whereas morphine induces negligible levels 
of phosphorylation and internalization. Moreover, the desensitization of µOR caused by 
chronic treatment with DAMGO is reversible whereas that produced by morphine is 
irreversible in this cell culture system (Schulz et al., 2004). 
Whistler et al., reported that in µOR expressing HEK293 cells, the rank order of 
selected agonists for inducing endocytosis was DAMGO = methadone >> morphine 
which means DAMGO and methadone causes similar levels of endocytosis of µOR 
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whereas morphine  causes negligible endocytosis. They also reported that other potent 
agonists like etorphine caused rapid endocytosis whereas mixed agonist/antagonist 
buprenorphine caused negligible receptor endocytosis. Further, GIRK–type potassium 
channels were over expressed in the HEK293 cells over expressing µOR and the ability 
of various agonists to activate these channel currents was tested to establish the rank 
order of the agonists wherein DAMGO and morphine produces similar levels of 
receptor-mediated activation of GIRK which is significantly greater than the GIRK 
activation produced by methadone (i.e. DAMGO ≥ Morphine >> methadone). The 
relative activity (as measured by the normalized current) versus endocytosis (RAVE) 
caused by various agonists were compared to reveal that when DAMGO has a RAVE 
value of 1, morphine has 3.8 (Whistler et al., 1999) which served as a guide to 
understand the ability of various agonists to cause tolerance development. Koch et al., 
demonstrated that the potency of a µ-opioid receptor agonist to induce receptor 
endocytosis is negatively correlated with its ability to cause development of tolerance in 
a cellular model (Koch et al., 2005). In line with this, Grecksch et al., demonstrated that 
in a rat model, buprenorphine and morphine which are known to cause very less or 
negligible internalization produced higher tolerance than etonitazine which is known to 
cause high internalization of µOR. They measured the antinonciceptive effects of these 
drugs at equieffective doses in a hot plate method and electric tail root stimulation 
method of nonciceptive stimulus (Grecksch et al., 2006). 
The phenomenon, wherein, different agonists acting on same receptor activates different 
downstream signaling pathways and different cellular responses is termed as functional 
selectivity or biased agonism or collateral efficacy. One of the explanations for such 
behavior could be that the physical interaction between the receptor and agonist will 
have conformational constraints leading to preference for a signaling pathway over 
other pathways (Kenakin, 2007, 2009). 
 
1.5 Functions of PI3Kγ  
PI3Kγ is classically known to be activated by Gi protein coupled GPCRs. Hence, 
cellular functions of PI3Kγ mostly involved stimulation of various GPCRs in respective 
cells. Generation of PI3Kγ knockout mice largely enabled the studies to reveal its 
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function in vivo.  Mice lacking PI3Kγ grow normally and they are fertile but when their 
immune system is stressed show clear-cut abnormalities (Hirsch et al., 2000b). 
 
1.5.1 Immune system related functions 
PI3Kγ is predominantly expressed in hematopoietic cells i.e. white blood cells – 
neutrophils, macorphages, T-cells and B- cells. N-formyl-Met-Leu-Phe (fMLP), a 
bacterial peptide, stimulates biphasic production of ROS (reactive oxygen species) in 
tumor necrosis factor-α (TNF-α)–primed human neutrophils. The initial phase of this 
biphasic response that occurs within 10 sec of exposure of fMLP is dependent on PI3Kγ 
as measured by the production of PtdIns(3,4,5)P3 (Condliffe et al., 2005). This initial 
phase of response is important for the second burst of ROS production that is largely 
governed by p110δ (Condliffe et al., 2005). Neutrophils and macrophages derived from 
PI3Kγ null mice exhibits severely impaired chemotaxis in response to various GPCR-
binding chemo-attractants like chemokines, fMLP, complement fragment C5a, in vitro. 
In vivo, in a mouse model of peritonitis, induced by injection of Gram-positive or 
Gram-negative bacteria, reduced accumulation of macrophages and reduced clearance 
of bacteria from peritoneal cavity observed in PI3Kγ null mice compared to wild type 
mice (Hirsch et al., 2000b). In a model of lung sepsis, broncho-alveolar leukocyte 
(neutrophils) recruitment required PI3Kγ (Yum et al., 2001) establishing the role of this 
class IB isoform in innate immunity and inflammation. Catalytic activity of p110γ is 
required for the neutorphil chemotaxis as the catalytically inactive PI3Kγ show 
chemotactic defect which is similar to that observed in the absence of PI3Kγ. The lipid 
kinase activity defines the direction of cell migration thus implying that PI3Kγ is 
required for directional sensing and function as a compass for inflammatory cells 
(Rickert et al., 2000). 
GPCR mediated signals that cause apoptosis and differentiation of T cells in 
CD4+/CD8+ helper or effector cells are dependent on PI3Kγ (Sasaki et al., 2000; 
Rodríguez-Borlado et al., 2003). Thymus development is severely reduced in mice 
lacking PI3Kγ although another PI3K isoform, PI3Kδ found to govern the  B cell 
maturation and function (Clayton et al., 2002) suggesting the role of PI3Kγ in adaptive 
immunity. Mastocytes are the first line of defense against invading pathogens releasing 
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many proinflammatory and vasoactive agents like histamine. Abnormal activity of mast 
cells was found in cases of allergy and asthma. Mast cell activation, triggered by 
antigen induced cross-linking of IgE immunoglobulin with FcεRI receptor triggers 
degranulation of mast cells, the initial phase of this event is controlled by PI3Kδ, 
whereas full degranulation of the mast cells required PI3Kγ (Sasaki et al., 2000; 
Laffargue et al., 2002; Ali et al., 2004; Hirsch et al., 2006). Essentially, PI3Kγ and δ 
plays a non-redundant, sequential role in mast cell activation. 
 
1.5.2 Vascular functions 
Expression of PI3Kγ in endothelial cells was reported earlier (Puri et al., 2005). 
Spingosine-1-phosphate (S1P), participates in endothelial cell migration and angiogenic 
differentiation by acting on Gi coupled receptor S1P1 and Gi/Gq/G12 coupled S1P3 
receptors. Heller et al., reported that PI3Kγ and PI3Kβ isoforms are involved in this 
signaling. The S1P induced phosphorylation of AKT was mediated predominantly by 
PI3Kβ isoform whereas the endothelial migration mediated via activation of Rac1 
which in turn dependent on both the isofroms PI3Kβ and PI3Kγ (Heller et al., 2008).  
Vecchione et al., reported the expression of p110γ in mouse aortic smooth muscle cells. 
Angiotensin II (AngII) is a peptide that acts as an endogenous agonist of GPCRs named 
AT1A in smooth muscle cells causing vasoconstriction. PI3Kγ is required for the AngII 
mediated activation of Rac and the subsequent triggering of ROS production in vascular 
smooth muscle cells. In addition, AngII–evoked Ca2+ flux is impaired in vessels from 
PI3Kγ knockout mouse. PI3Kγ mediated phosphorylation of AKT in these cells governs 
the L-type Ca
2+ 
channel-mediated extracellular Ca
2+ 
entry. Taken together these two 
signaling events protect PI3Kγ knockout mouse from AngII induced hypertension 
(Vecchione et al., 2005). In rat portal veins, PI3Kγ can be activated by β1γ3 dimer of 
AT1A receptor upon stimulation with Ang II (Viard et al., 1999) as evidenced by 
blockade of production of PtdIns(3,4,5)P3 and calcium influx by antibodies inhibiting 
PI3Kγ (Quignard et al., 2001). 
PI3Kγ is expressed in airway smooth muscle cells of mouse trachea and lung. 
Acetylcholine (ACh) stimulated contraction of cultured precision–cut lung slices was 
mediated by PI3Kγ as evidenced by its inhibition by PI3Kγ specific inhibitor. 
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Moreover, Jiang et al., also showed that other PI3K isoforms do not inhibit ACh 
induced contraction of smooth muscle cells of lungs. At the cellular level, 
pharmacological inhibition of PI3Kγ inhibited the ACh induced Ca2+ oscillations in 
individual airway smooth muscle cells from mouse lung slices that are essential for 
sustained contraction (Jiang et al., 2010).  
Platelet aggregation might be dependent on PI3Kγ, at least partially. Mouse platelets 
lacking PI3Kγ exhibit only partial aggregation defect. Generally, platelets contain Gαi 
as well as Gαq type of GPCRs. These receptors can be stimulated by agonists ranging 
from thrombin to thromboxane and ADP. PtdIns(3,4,5)P3 production stimulated by 
P2Y12 (purinergic P2Y, G-protein coupled, 12) receptors which are coupled to Gi-
protein was PI3Kγ dependent whereas PtdIns(3,4,5)P3 production by P2Y1 receptors 
that are coupled to Gq-protein was not dependent on PI3Kγ. ADP stimulation of PI3Kγ 
null platelets causes weak but significant reduction of fibrinogen binding along with 
weak aggregation defect and thromboembolism which might have been mediated by 
Rap1B, a small GTPase. In addition, p110γ knockout platelets show increased cAMP 
levels (Hirsch et al., 2001; Hirsch et al., 2006). 
Phenotypic differences between PI3Kγ knockout and PI3Kγ kinase dead versions were 
reported in case of endothelial progenitor cells (EPCs). PI3Kγ kinase dead mice develop 
vascular collaterals whereas PI3Kγ knockout mice present impairment in post–ishemic 
hind limb angiogenisis indicating a kinase-independent function of PI3Kγ (Madeddu et 
al., 2008).  
 
1.5.3 Cardiac Functions 
In cardiomyocytes, the platelet activating factor (PAF) induced negative inotropism is 
dependent on PI3Kγ. Binding of PAF to Gi-coupled GPCR in these cells induces 
activation of PI3Kγ followed by PtdIns(3,4,5)P3 production and activation of AKT 
resulting in subsequent stimulation of NO synthesis (Alloatti et al., 2003) and negative 
inotropism. Both lipid kinase and protein kinase activities of p110γ play pivotal roles in 
β-adrenergic receptor endocytosis. PIK domain of P110γ interacts with β-ARK1 (β-
adrenergic receptor kinase-1) and gets targeted to agonist occupied receptor triggering 
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localized production of PtdIns(3,4,5)P3 for the organization of clathrin-coated pits 
driving receptor internalization (Naga Prasad et al., 2005). 
Differences in phenotypes of PI3Kγ knockout and PI3Kγ kinase dead versions revealed 
scaffolding functions of p110γ. Transverse aortic constriction leads to cardiac pressure 
overload, subsequent cardiac remodeling and heart failure. In response to transverse 
aortic constriction, PI3Kγ kinase dead mice developed similar adaptive responses as of 
control mice whereas PI3Kγ knockout mice developed rapid, fatal cardiac myopathy. 
Cardiac contractility is affected by cAMP concentrations and PDE3B controls the local 
concentrations of cAMP by accelerating its degradation. p110γ binds to PDE3B and 
increases its phosphodiesterase activity leading to increased hydrolysis of cAMP, 
negatively regulating the cardiac contractility (Patrucco et al., 2004). In addition, 
cardiac myocytes from PI3Kγ knockout mice show increased cAMP levels whereas 
cardiac myocytes from PI3Kγ kinase dead mice and control mice show similar cAMP 
levels. IBMX treatment of cardiac myocytes from PI3Kγ kinase dead mice and control 
mice show increased cAMP
 
levels that are comparable to the cAMP levels in cardiac 
myocytes from PI3Kγ knockout mice. Further, Patrucco et al., showed that the 
phosphodiesterase activity of PDE3B in immunoprecipitates from cardiac extracts of 
PI3Kγ knockout mice was reduced compared to that of PI3Kγ kinase dead or PI3Kγ wild 
type cardiac extracts. Taken together, they indicated that PI3Kγ interacts with PDE3B 
and regulates intracellular cAMP levels through kinase-independent functions (Patrucco 
et al., 2004). Subsequently, Perino et al., showed that p110γ forms a macro molecular 
complex tethering together p84/87-PKA-PDE3B. This association leads to 
phosphorylation of p110γ and PDE3B by PKA giving rise to increased 
phosphodiesterase activity of PDE3B and reduced lipid kinase activity of p110γ. This 
further demonstrates the scaffold functions of PI3Kγ in cardiomyocytes connecting 
cAMP-AKT pathways (Perino et al., 2011).  
Cardiomyocytes lacking PI3Kγ show higher basal cAMP levels and higher basal 
intracellular Ca
2+
 densities. Forskolin induced activation of adenylyl cyclase is 
unaltered in wild type and PI3Kγ knockout cardiomyocytes suggesting that PI3Kγ does 
not affect adenylyl cyclase directly. Specific inhibition of PDE3B by milrinone or 
general inhibition of phosphodiesterases by IBMX increases the L-type calcium 
currents in wild type myocytes compared to PI3Kγ knockout myocytes, in basal 
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conditions. Moreover, lack of p110γ increases the sensitivities of myocytes to β-
adrenergic receptor stimulation. Isoproterenol treatment of adult mouse ventricular 
myocytes increases the L-type calcium currents significantly higher in wild type cells 
compared to PI3Kγ knockout cells. This increase is further augmented by milrinone 
treatment only in wild type cells but not in PI3Kγ knockout cells. Taken together, these 
data suggests that phosphodiesterase activity of PDE3B is regulated by PI3Kγ in basal 
conditions as well as after β-adrenergic receptor stimulated conditions (Marcantoni et 
al., 2006). 
 
1.5.4 Neuronal functions: Involvement of PI3Kγ in µOR mediated 
signal transduction  
PI3Ks play pivotal role in various neuronal functions affecting neuronal plasticity, long-
term potentiation (LTP), learning and memory (Opazo et al., 2003; Horwood et al., 
2006; Ran et al., 2009). PI3K isoforms show different expression patterns in various 
parts of the brain suggesting involvement of specific isoforms in specialized neural 
functions, although experimental evidence is largely required to confirm this 
speculation. Towards this end, recent reports suggested involvement of PI3Kγ in 
NMDAR (N-methyl-D-glutamate aspartate receptor) dependent long-term depression 
(LTD) and behavioral flexibility. In their studies Kim et al., showed the differential 
expression of PI3K isoforms. PI3Kγ was detected in crude synaptosomal membranes 
and synaptosomal fractions whereas P110α was detected in crude cytosolic S2 fraction. 
In line with their differential expression pattern PI3Kγ selective inhibitor inhibited 
homosynaptic NMDAR LTD whereas PI3Kα selective inhibitor did not. Thus they 
reported that PI3Kγ was specifically involved in induction phase of NMDAR LTD as 
evidenced by its selective impairment in PI3Kγ knockout mice. At signal transduction 
level it was shown that NMDA induced p38 MAPK activation was impaired in PI3Kγ 
knockout mice compared to wild type mice. In hippocampal slices, NMDA stimulation 
of NMDA receptor leads to Gβγ independent, PI3Kγ dependent activation of p38 
MAPK and it was reported as the possible mechanism of involvement of PI3Kγ in 
impairment of homosynaptic NMDA receptor LTD (Kim et al., 2011). 
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Expression of PI3Kγ in mouse olfactory epithelium was reported by Brunert et al., 
recently. They showed that PtdIns(3,4,5)P3 production was abolished in olfactory 
receptor neurons (ORNs) from PI3Kγ knockout mice compared to ORNs from wild 
type mice, in response to odorant Henkel 100 stimulation. This suggests the 
involvement of PI3Kγ dependent signaling in olfactory neurons (Brunert et al., 2010). 
Narita et al, reported the molecular evidence of activation of PI3Kγ by stimulation of 
µOR. In their experiments they showed the expression of PI3Kγ in mouse 
periaquiductal gray (PAG) at plasma membrane and cytoplasm. In addition, they 
showed the co-localization of PI3Kγ with µOR at the plasma membrane (Narita et al., 
2004). They also reported that single subcutaneous injection of morphine could result in 
two fold increase in the immunoreactivity of PI3Kγ at the plasma membrane in mouse 
PAG. Moreover, the higher immunoreactivity of phosphorylated PLCγ1 (phospholipase 
Cγ1) was noticed and interestingly, this was co-localized with PI3Kγ immune reactivity 
at the plasma membrane. Since, PLCγ1 is known to contain PH domain and an effector 
protein of PtdIns(3,4,5)P3 (Falasca et al., 1998), it might suggest possible involvement 
of PI3Kγ- PtdIns(3,4,5)P3-PLCγ in morphine induced antinonciceptive effects. In in 
vivo experiments they found that intracerebroventricular injection of wortmannin or 
LY294002 in mice inhibited the morphine evoked antinonciceptive effects as evidenced 
by rightward shift of dose-response curves in a warm plate test (Narita et al., 2004). 
Opioid analgesics are excellent pain relieving agents that acts predominantly via µOR 
which is a GPCR coupled to Gαi/o type of G-protein. Morphine and DAMGO, acting 
on µOR, can inhibit the Ca
2+
 currents through voltage-gated Ca
2+ 
channels (VGCC). 
This requires direct interactions of Gβγ with Ca2+ channels. Long-term administration of 
DAMGO or morphine can cause desensitization of µOR resulting in abolition of 
inhibition of Ca
2+
 currents through VGCC in mouse DRG neurons. Chronic DAMGO 
induced desensitization of µOR was enhanced in PTEN knockout mice DRGs which 
result in constitutive activation of AKT. Moreover, pharmacological inhibition of PI3K 
and MAPK also attenuated the chronic DAMGO induced desensitization of µOR in 
mouse DRGs as measured by Ca
2+
 flux through VGCC (Tan et al., 2003). In line with 
this, long-term treatment (6 h bath application of DAMGO) produced desensitization of 
µOR in wild type DRG neurons but not in DRGs from PI3Kγ knockout mice as 
measured by the Ca
2+
 currents via VGCC (König et al., 2010). Similar behavior was 
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observed with DRGs from PI3Kγ kinase dead mice. In addition, reconstitution of PI3Kγ 
knockout DRGs with PI3Kγ lead to restoration of desensitization of µOR as evidenced 
by the response to acute administration of DAMGO, following long–term treatment 
with DAMGO to induce desensitization, which was comparable to wild type response. 
This suggested the requirement of enzymatic function of PI3Kγ for the long–term 
treatment induced desensitization of µOR. Further, pharmacological inhibition of PKC 
by bis-indolyl-maleinimide also abolished the DAMGO induced desensitization in wild 
type DRG neurons. Supporting the above data, administration of repeated escalating 
doses of morphine over a period of 4 days induced less tolerance development in PI3Kγ 
knockout
 
mice compared to wild type mice in a tail-flick test (König et al., 2010). Since 
PKC is classically reported to be involved in desensitization of µOR (Kelly et al., 2008) 
and PKCα was shown to interact with PK3Kγ (Lehmann et al., 2009) it might be 
possible that µOR desensitization could be mediated by interactions of PI3Kγ and PKC. 
Morphine causes increase in whole cell potassium currents in cultured mouse DRG 
sensory neurons. This hyperpolarizes the nonciceptive neurons and thus morphine 
attenuates PGE2 induced depolarization of neurons resulting in antinoncieptive effects. 
Morphine also stimulates activation of AKT, eNOS (nitric oxide synthase) and 
subsequently nitric oxide production leading to peripheral analgesia in a mouse model 
of PGE2 (prostaglandin E2) induced hypernonciception (Cunha et al., 2010). 
The mechanism of peripheral analgesia induced by morphine involves on one hand 
activation of AKT leading to subsequent stimulation of NO synthesis (Cunha et al., 
2010) on the other hand depends on cAMP mediated of inhibition of TRPV1 (transient 
receptor potential vanilloid receptor-1) currents (Endres-Becker et al., 2007). Thus two 
pathways lead to comparable physiological function. 
In general, µOR is a GPCR that classically couples to Gi proteins exhibits signal switch 
and variable desensitization patterns leading to tolerance development. The molecular 
mechanisms of these processes are still under investigations by many investigators. 
PI3Kγ is proved to be involved in GPCR mediated signaling. Increasing evidence is 
accumulating in the direction of involvement of PI3Kγ in µOR signaling pathways that 
leads to peripheral analgesia. This motivated us to investigate the role of PI3Kγ in 
signal transduction mediated by µOR upon stimulation with morphine and forms the 
basis for our current investigations. 
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1.6 Aim of the current work 
Previous reports indicates that PI3Kγ has kinase-independent activities in heart that 
exert a negative feed-back control on intracellular cAMP levels affecting myocardial 
contractility (Patrucco et al., 2004). In cardiomyocytes, the multiprotein complex of 
p84/87-p110γ-PKA-PDE3B results in phosphorylation of p110γ and PDE3B by PKA 
affecting the enzymatic functions of p110γ and PDE3B. The lipid kinase activity of 
p110γ was inhibited and phosphodiesterase activity of PDE3B was stimulated by this 
complex formation where PI3Kγ functions as an anchoring protein (Perino et al., 2011).  
König et al., reported that PI3Kγ knockout mice showed reduced tolerance development 
in response to repeated morphine administration compared to wild type mice. Further, 
chronic DAMGO induced desensitization of µOR is mediated by PI3Kγ through its 
kinase dependent functions (König et al., 2010).   
In the light of the discovery of kinase–independent functions of PI3Kγ in case of 
cardiomyocytes, we wanted to explore the kinase–independent functions of PI3Kγ in 
neuronal cells following stimulation of µOR with morphine. Hence, in the current work, 
we explored i) the crosstalk between cAMP – AKT pathways and ii) functioning of 
PI3Kγ as a nodal point connecting the two pathways following stimulation of µOR with 
morphine on a functional scale.  
In order to study this, we used a model system of SK-N-LO cells (cells with normal 
levels of PI3Kγ and cells with down-regulated levels of PI3Kγ) expressing µOR and 
dorsal root ganglion neuronal cells from wild type and PI3Kγ knockout mice. We 
investigated the effects of altered PKA levels brought about by the activation of 
adenylyl cvclase and direct inhibition of PDEs or PKA, on morphine induced activation 
of protein kinase B (AKT) in presence and absence of PI3Kγ. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Plasmids 
 pcDNA3.1-HA-mOPRM1 wt encoding mouse µOR plasmid (Kindly provided 
by Prof. Schultz Institute of Pharmacology and Toxicology, University Hospital, 
Jena, Germany). 
 pLKO.1-puro derivative plasmids carrying shRNA target sequences  (as shown 
in Table 2.1) 
 
Table. 2.1 shRNA plasmid sequences 
Plasmid 
(code) 
shRNA sequence 
Clone ID (Sigma 
Aldrich) 
PI3Kγ 
(γ1) 
CCGGGCAACCTTTGTTCTTGGAATACTCGAGTATTCCAAGAACAAAGGTTGCTTTTTG 
NM_002649.2-
3122s1c1 
 
PI3Kγ 
(γ3) 
CCGGGCCCTATCAAATGAAACAATTCTCGAGAATTGTTTCATTTGATAGGGCTTTTTG 
NM_002649.2-
2774s1c1 
 
PI3Kγ 
(γ5) 
CCGGCCTGTGGAAGAAGATTGCCAACTCGAGTTGGCAATCTTCTTCCACAGGTTTTTG 
NM_002649.2-
940s1c1 
 
--------- 
(control) 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT 
Lentiviral non 
targeting control 
vector (SHP002) 
 
 Lentiviral packaging plasmids MDL, RSV and VSV were kindly provided by C. 
Stocking, HPI, Hamburg from their laboratory collection. 
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2.1.2 Cell lines 
Cell line Type Source 
SK-N-LO 
Human neuroblastoma cell line, 
adherent 
Childern’s University 
Hospital, Tübingen, 
Germany (Volker et al., 
2010) 
HEK293T  
Human embryonic kidney cell line, 
packaging cells, adherent 
C. Stocking, HPI 
Hamburg 
 
 
2.1.3 Antibodies 
 PI3Kγ monoclonal antibody, directed against whole protein PI3Kγ (# 641) 
(Produced in the Institute of Molecular Cell Biology, CMB, FSU Jena) 
 µOR monoclonal antibody (Lupp et al., 2011) (Kindly provided by Prof. Schultz 
Institute of Pharmacology and Toxicology, University Hospital, Jena, Germany) 
 HA (tag) monoclonal antibody (New England biolabs GmbH, Frankfurt, 
Germany cat. no. 2367) 
 Phospho AKT serine 473 antibody (Cell Signaling Technology, Frankfurt, cat. 
no. 9271S) 
 Phosphorylated AKT threonine 308 antibody (Cell Signaling Technology, 
Frankfurt, cat. no. 9275S) 
 Pan AKT antibody (Cell Signaling Technology, Frankfurt, cat. no. 9272S) 
 Phospho ERK1/2 monoclonal antibody (Cell Signaling Technology, Frankfurt, 
cat. no. 9106S) 
 Pan ERK1/2 monoclonal antibody (Cell Signaling Technology, Frankfurt, cat. 
no. 4695S) 
 β-actin monoclonal antibody (Sigma, cat. no. A5441) 
 Vinculin monoclonal antibody (Biozol, Eching, cat. no. BZL-03106) 
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 Peroxidase labeled affinity purified antibody to rabbit IgG (H+L) produced in 
goat (Kirkegaard & Perry laboratories, Weden, cat. no. 074-1506) 
 Peroxidase labeled affinity purified antibody to mouse IgG (H+L) human serum 
adsorbed produced in goat (Kirkegaard & Perry laboratories, Weden, cat. no. 
074-1806) 
 AlexaFluor®488 – Immunofluorecesence secondary antibody  (Invitrogen Life 
technologies) 
 
 
Usage of antibodies for immunoblotting: 
Antibody  SK-N-LO cells DRGs  
PI3Kγ    1:100  - 
µOR    1:200  1:20 (Immunocytochemistry) 
 P-AKT serine 473  1:1000  - 
P-AKT threonine 308  1:1000  1:500 (Zhuang et al., 2004)  
AKT    1:1000  1:500 (Zhuang et al., 2004) 
P-ERK1/2   1:1000  1:1000 
ERK1/2   1:1000  1:1000 
β-actin    1:5000  - 
Vinculin   1:5000  - 
Anti-mouse secondary  1:10,000 1:10,000 
Anti-rabbit secondary  1:5000  1:5000 
AlexaFluor
®
488 secondary -  1:1000 
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2.1.4 Drugs and inhibitors  
Table. 2.2 Drugs and inhibitors used. 
Drugs/Inhibitors Target Source 
Morphine µOR agonist Sigma 
Naloxone Specific µOR antagonist Sigma 
Pertussis toxin 
(PTX) 
Gi – protein coupled GPCR inactivator Enzo Life Sciences 
Wortmannin Pan PI3K inhibitor Sigma 
AS605240 PI3Kγ inhibitor Axxora GmbH 
A66  S isomer PI3Kα inhibitor Symansis 
TGX221 PI3Kβ inhibitor 
Baker Heart 
Institute 
IC87114 PI3Kδ inhibitor 
Baker Heart 
Institute 
Forskolin Adenylyl cyclase activator Enzo Life Sciences, 
IBMX 
Non-selective Phosphodiesterase 
inhibitor 
Sigma 
H-89 PKA inhibitor Enzo Life Sciences, 
 
2.1.5 Chemicals  
Substance      Source 
HEPES      Roth  
EGTA       AppliChem  
β-Glycerophosphate      SERVA  
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MgCl2.6H2O      Roth  
Microcystin       Axxora  
Pepstatin       AppliChem  
Leupeptin       AppliChem  
Pefa bloc – AEBSF-HCl     AppliChem  
Sodium orthovanadate     Sigma –Aldrich  
PMSF        SERVA  
NP40        Calbiochem  
Sodium Azide      Roth  
Bovine serum albumin – BSA    PAA  
Non-fat dried Milk powder     AppliChem  
β-Mercaptoethanol      Roth  
Polyacrylamide – RotiPhorese® Gel 30 (37.5:1)  Roth  
Tris        AppliChem  
Glycine       Roth  
Sodium dodecyl sulphate – SDS    AppliChem  
Ammonium persulphate – APS    SERVA  
TEMED       Promega  
PVDF membrane      Immobilon
®
  
Methanol       Roth  
Tween-20       SERVA  
Triton X-100       Roth  
ECL solution       Perkin Elmer  
Sodium Chloride      Roth  
Lectin beads       Sigma  
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Bromophenolblue      Bio-Rad  
Ampicillin       Roth 
 
2.1.6 Cell culture media and additives 
Substance      Source 
 Fetal Calf Serum (FCS)    Gibco 
 L-Glutamine      PAA 
 Penicillin/Streptomycin    PAA  
 Collagenase: type 2     PAA  
 1x Trypsin/EDTA     PAA  
 Sigmacote      Sigma 
 Poly-L-Lysine – PLL     Sigma 
 Dimethylsulfoxide (DMSO) HUBRI MAX®  Sigma Aldrich  
 IMDM       PAA  
 HAM’S F12      PAA 
 G418 – (G418 sulphate)    PAA  
 Puromycin – (Puromycin dihydrochloride)  Sigma 
 Normal goat serum     DAKO Diagnostika 
 
For shRNA experiments 
 Dulbecco modified Eagle medium (DMEM/F12) (GIBCO-Life Technologies, 
Germany)  
 Defined fetal calf serum (Sigma-Aldrich, cat. no. F-7524) 
 0.2 μm low-protein binding syringe filter holders (Sartorius, Germany, cat.no. 
16534 K) 
 PEI, Polyethylenimine (Sigma-Aldrich, cat. no. 40872-7) 
 Polybrene (1,5-dimethyl-1,5-diazaundecamethylene polymethobromide, Sigma-
Aldrich, cat. no. AL-118, cat. no.  10,768-9) 
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 EndoFree Plasmid Maxi Kit (Qiagen, Weden, Germany, cat. no. 12362) for 
plasmid isolation 
 
2.1.7 General solutions and other materials 
 
Lysis buffer  20 mM   HEPES buffer pH 7.5 
10 mM   EGTA 
40 mM   β-glycerophosphate 
1 %    NP-40 
2.5 mM   MgCl2 
Adjust the pH to 7.5 
 Added protease and phosphatase inhibitors, just before use (final concentration), 
100 µg/ml AEBSF 
1 mM   PMSF 
1 mM   Vanadate 
1 µg/ml  Pepstatin A 
1 µg/ml  Leupeptin 
3.4 nM  Microcystin  
1 mM   β-glycerophosphate 
 
LB Medium  10 g   Bacto – tryptone  
   5 g   Bacto-yeast extract 
   10 g   NaCl 
Milli Q Water to 1 Liter, autoclave to sterilize 
 
10x TBS   0.05 M  Tris 
0.5 M   NaCl 
 
TBS-Tween (TBS-T)  1x   TBS 
    0.01 %  Tween 20 
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Separation gel buffer 2 M  Tris  pH 8.8 
 
Stacking gel buffer  0.5 M  Tris  pH 6.8 
 
20 % APS   20 % Ammonium per sulphate in Milli Q water 
 
10 x PAGE buffer  250  mM Tris 
2 M  Glycine 
35 mM  SDS 
pH is about 8.7 do not adjust 
 
Blocking solution  2.5 % Bovine serum albumin (BSA) in 1x TBS-T 
 
5 % Milk solution 5 % Non-fat dried milk powder in 1x TBS-T 
 
Transfer buffer  48 mM   Tris 
39 mM   Glycine 
0.037 %   SDS 
20 %    methanol 
pH is between 9-10 do not adjust the pH 
 
Stripping solution  100 mM β- Mercaptoethanol 
2 %   SDS 
62.5 mM Tris pH 6.7 
 
5x Laemmli buffer Glycerin   4 ml 
20 % SDS   3 ml 
β-mercaptoethanol  3 ml 
1 % Bromophenolblue 200 µl 
0.5 M Tris   2 ml 
Aliquots stored at -20 
o
C 
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RIPA buffer-(Radio immuno precipitation assay buffer) 
150 mM  NaCl 
50 mM  Tris HCl pH7.4 
5 mM   EDTA 
1%  Nonidet P-40 
0.5 %   Na-deoxycholate 
0.1 %   SDS 
Mix NaCl, EDTA and Tris, then adjust pH to 7.4 then add other ingredients 
 
Zamboni Fixing solution 350 ml  Saturated picric acid 
 80 g   Paraformaldehyde 
in 500ml bottle warm up to 60°C  
add drop wise 2,5 % NaOH until PFA is dissolved totally 
filter in 2 liter-bottle and fill up with PB-buffer up to 2 liter 
 
PB-buffer Zamboni  200 mM  NaH2PO4 133 ml 
200 mM  Na2HPO4  567 ml 
Fill up to 1 liter with Milli Q H2O 
 
0,1 M PB-buffer for immunocytochemistry: 
0,5 M  Na2HPO4  154.8  ml 
1 M  NaH2PO4  22.6 ml 
fill up with Milli Q H2O to 1 liter, 
Add 1 ml Triton-X 100 for immunocytochemistry 
 
TE (10:1)Buffer   10 mM  Tris-HCl, pH 7.6,  
1 mM   EDTA 
 
5x PBS   500 mM  NaCl 
100 mM  Na2HPO4 
400 mM  NaH2PO4 
Dilute to 1x with Milli Q Milli Q H2O and adjust pH to 7.4 
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 Poly-L-Lysine (PLL) – Working solution 50 µg/ml in Milli Q water 
 
 Polyethylenimine (PEI) – stock solution 10 g/l in H2O 
 
 G418 – 100 mg/ml stock solution in 100 mM HEPES buffer pH 7.5 – filter 
sterilized using 0.22 µ filter  
 Puromycin – 2 mg/ml stock solution in 100 mM HEPES buffer pH 7.5 – filter 
sterilized using 0.22 µ filter 
 Coating of Pasteur pipette: Pipette 4-5 times up and down with the solution 
Sigma cote
®
 and flame Pasteur pipette. Then sterilize them. 
 Luminescent Image Analyzer-Image Reader (FUJI Film LAS 4000) 
 Tissue culture flasks (Nunc, Germany) 
 6-well tissue culture plates (Nunc, Germany, cat. no. 140675) 
 12-well tissue culture plates (Nunc, Germany, cat. no. 150628) 
 Whatmann filter Paper (Macherey-Nagel, Germany) 
 Bio-Rad power supply (model no. 1000/500) 
 Semi-dry transfer cell (Trans-Blot® SD) 
 Laser scanning microscope (Zeiss LSM 510 Meta) 
2.1.8 Animals  
DRGs were collected from adult wild type and PI3Kγ-/-mice (C57/B6J). Animals were 
housed four to six in a cage and maintained in a 12 h day/light cycle in a temperature 
controlled environment with unrestricted access to food and water.12-14 week old mice 
were used for experiments. The wild-type and PI3Kγ-/-mice were derived by 10 
generations of successive backcrosses of heterozygous male knockout mice from 
chimeric C57BL6/129Sv PI3Kγ-/-mice (Hirsch et al., 2000) with C57BL/6 females 
(Jackson Laboratories, USA). 
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2.2 Methods 
2.2.1 m-µOR plasmid amplification 
Medium scale plasmid preparation was performed using Qiagen Midi Prep Plasmid Kit, 
according to the manufacturer’s instructions. E. coli TO1 pcDNA3.1-HA-mOPRM1 wt 
was grown in 100 ml LB medium overnight. The bacterial cells were harvested by 
centrifugation at 6000 x g in a Sorvall centrifuge for 15 min at 4 
o
C. The bacterial pellet 
was resuspended in 10 ml of resuspension buffer (50 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 100 mg/ml RNase A). 10 ml of lysis buffer (200 mM NaOH, 1 % SDS) was 
added, mixed gently and incubated at room temperature for 5 min. 10 ml of chilled 
neutralization buffer (3.0 M potassium acetate, pH 5.5) was added, mixed immediately, 
but gently and incubated on ice for 15-20 min. Samples were centrifuged once again. 
Supernatant was applied to a Qiagen-tip previously equilibrated with 10 ml of 
equilibration buffer (750 mM NaCl, 50 mM MOPS, pH 7.0, 1% ethanol) to bind 
plasmid DNA to the column and washed with another 10 ml to remove the 
carbohydrates of the bacterial strains. The DNA was eluted in 15 ml of elution buffer 
(1.25 M NaCl, 50 mM Tris-HCl, pH 8.5, 15 % ethanol) precipitated with 0.7 volumes of 
room temperature isporopanol and immediately centrifuged at 15000 x g for 30 min at 4 
o
C and the supernatant was removed carefully. The DNA was washed with 5 ml of 70 % 
ethanol. Air-dried for 5 min and redissolved in a 30 ml of TE Buffer. The DNA 
concentration was determined spectrophotometrically. Quiagen purified DNA was used 
for transfection of the cells. 
 
2.2.2 Cell culture conditions  
 General media for SK-N-LO cells: 1:1 mixture of IMDM : HAM’S F12  
supplemented with 10 % FCS. 
 Media for m-µOR SK-N-LO cells: 1:1 mixture of IMDM : HAM’S F12  
supplemented with 10 % FCS and 1 mg/ml G418. 
 Media for shRNA treated m-µOR SK-N-LO cells: 1:1 mixture of IMDM : 
HAM’S F12  supplemented with 10 % FCS and 1 mg/ml G418 and 1 µg/ml 
puromycin. 
Materials and Methods | 33 
 
 
 
Cultivation of cells: SK-N-LO (and all the other cells generated) cells were grown in 
T-75 flasks with a filter containing screw capped lid, in a humidified atmosphere 
containing 5% CO2 at 37 
o
C. The cells were maintained by regular splitting avoiding 
excessive densities. Handling of cells was done in sterile laminar air flow unit avoiding 
contaminations. 
Trypsinization: Media was aspirated from the flask. The cells were washed once with 
1x PBS. 1 ml trypsin was added to the cells in T-75 flask, incubated for 2 – 5 min, 
gently tapped to detach the cells from the flask surface and new medium was added. 
Generally, 1:5 or 1:8 split was done twice a week. 
Storage of cells: The cells were grown to 80 % confluence in T-175 flasks. Following 
trypsinization, the cells were added with FCS containing 10 % DMSO and dispensed in 
storage vials in aliquots of 1 ml each containing around 1-2 X 10
6 
cells. The vials were 
stored at -150 
o
C. 
Thawing of the cells: A freeze stock of cells was warmed to 37 
o
C for 3 – 5 min, 
transferred to an Eppendorf’s tube centrifuged at 1200 rpm for 5 min. The DMSO 
containing medium was removed and the cells were resuspended in appropriate growth 
media and transferred to T-75 tissue culture flask.  
 
2.2.3 Transfection of SK-N-LO cells 
SK-N-LO (Human neuroblastoma cell line) cells were grown in a 1:1 mixture of IMDM 
and HAM’S F12 media supplemented with 10 % FCS. The cells were split and 
200,000-300,000 cells/well were seeded into a 6-well plate. Next day, sub confluent 
cells were transfected with 2 – 3 µg mouse µOR plasmid wild type following a PEI 
transfection protocol.  
Mix of DNA was prepared in an Eppendorf tube (final volume 1 ml) 
Tube 1: DNA (2-3 µg) + 500 µl of 1:1 mixture of IMDM:HAM’S F12 media 
without serum  
Tube 2: PEI (2.5 µg/1 µg DNA) + 500 µl of 1:1 mixture of IMDM:HAM’S F12 
media without serum  
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Tube 2 contents were added to Tube 1 content, mixed gently and kept at room 
temperature for 30 min. 
Cells were washed twice with warm 1:1 mixture of IMDM:HAM’S F12 media without 
serum. DNA – PEI mixture was carefully added to the cells.  The plate was incubated in 
a CO2 incubator at 37 
o
C for 6 h. The PEI containing media was replaced with 1:1 
mixture of IMDM:HAM’S F12 media containing 10 % FCS. Two days after the 
transfection SK-N-LO cells were selected with 1 mg/ml G418 for 2 weeks. Surviving 
cells were further propagated in tissue culture flasks and analyzed for expression of 
PI3Kγ and µOR. 
 
2.2.4 Expression analysis of PI3Kγ 
The cells (400,000-600,000) were lysed in 200 µl of ice cold lysis buffer containing 
protease and phosphatase inhibitors. The cells were incubated on ice for 10 min, then 
the samples were scraped and collected into Eppendorf’s tubes and centrifuged at 
14,000 rpm for 20 min at 4 
o
C. 160 µl of the cell lysate supernatants were added with 40 
µl of 5x SDS-sample buffer. The samples were heated at 95 
o
C for 5 min. The samples 
were resolved by 10 % SDS-PAGE. 
 
2.2.5 Expression analysis of µOR 
800 µl of RIPA buffer with necessary protease and phosphotase inhibitors was added to 
the cells (400,000-600,000) in 6 well plates and incubated on ice for 10 min. The 
samples were scraped and collected into Eppendorf’s tubes and centrifuged for 30 min 
at 14,000 rpm, at 4 
o
C. These cell lysate supernatants were transferred to new tubes 
containing 40 µl of lectin beads. The tubes were kept on rotation for 2 h at 4 
o
C. The 
tubes with cell lysate and beads were centrifuged for 5-9 sec and the supernatant was 
transferred to another tube and used for loading control analysis. The beads were 
washed with ice cold RIPA buffer three times. The remaining liquid was aspirated with 
insulin syringe. Subsequently, 60 µl of 2x SDS-sample buffer was added to the beads 
and heated at 60 
o
C for 20 min with constant mixing. Thus prepared samples were 
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resolved by 7.5 % SDS-PAGE. Additionally, 160 µl of above supernatant was added to 
40 µl of 5x SDS sample buffer and the sample was cooked for 5 min at 95 
o
C, which 
was used for loading controls.  
 
2.2.6 Stimulation experiments using SK-N-LO cells  
SK-N-LO cells stably transfected with mouse µ-opioid receptor, further referred to as 
m-µOR SK-N-LO cells, were seeded in 6-well plates. After 24 h the medium was 
replaced with serum free media (containing 1:1 mixture of IMDM:HAM’S F12 + 1 
mg/ml G418) and incubated for 12 h before the experiment (starvation period). In a 
typical experiment, serum starved cells were preincubated with selected inhibitors or 
vehicle in serum free media (containing 1:1 mixture of IMDM:HAM’S F12) for 
indicated time before stimulation with morphine. Incubation time for pertussis toxin 
was for 12 h (began with starvation period). Immediately following stimulation, the 
cells were lysed in 200 µl of ice cold lysis buffer containing protease and phosphatase 
inhibitors.  The samples were processed for Western blot analysis as described under 
expression analysis of PI3Kγ. The proteins were resolved by 10 % SD-PAGE and 
immunoblotted with appropriate antibodies. 
 
2.2.7 shRNA mediated down regulation of PI3Kγ in m-µOR SK-N-LO 
cells 
Knockdown of PI3Kγ in m-µOR SK-N-LO cells was accomplished by shRNA method. 
The following steps were involved in this process. 
- Production of lentiviral particles  
- Transduction of m-µOR SK-N-LO cells 
Production of lentiviral particles 
 7-8 x105 HEK293T cells per dish were seeded into seven 10 cm dishes. The 
cells were distributed evenly in the dish. 
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 The cells in 10 cm dishes were incubated at 37 C overnight. Next day 
transfected with packaging plasmids. 
Procedure of transfection as follows 
 DMEM/F12 medium without FCS was prewarmed to room temperature. 10 g 
lentiviral expression plasmid (pLKO.1-derivative plasmids encoding the shRNA 
genes) and the ready prepared lentiviral packaging mix were diluted in 
DMEM/F12 as mentioned below. In parallel pLKO.1 derivative plasmid 
encoding a nontargeting shRNA prepared, as described below. 
1) 3.5 ml of DMEM-F-12 media without FCS + 17.5 µl of PEI (10 µg/ml 
solution) (2.5 µg/ µg of DNA) 
2) 3.5 ml of DMEM-F-12 media without FCS + pMDL + pVSV + pRSV 
(packaging mix) 
 Plasmid  amount (µg)/10 cm dish 
pMDL   10 
pVSV   2 
pRSV   5 
 
 500 µl of packaging mixture prepared above was dispensed into seven 
Eppendorf’s tubes labeled as γ1, γ3, γ5, control & green (GFP encoding 
reference plasmid). 
 Lentiviral expression plasmids were added to the 7 tubes, as mentioned below 
Plasmid ID    code amount(µg)/ dish   
NM_002649.2-3122s1c1 γ1  2 
NM_002649.2-2774s1c1 γ3   2 
NM_002649.2-940s1c1 γ5  2 
Lentiviral nontargeting control  Control 2 
GFP encoding reference plasmid  Green  2 
 
Materials and Methods | 37 
 
 
 
 500 µl PEI solution prepared above was added to each tube containing lentiviral 
expression plasmid. 
 The contents of the tube were mixed thoroughly immediately after addition and 
vortexed. Then incubated for 30 min at 37 
o
C. 
 The FCS-containing media in HEK293T cells seeded dishes was replaced with 
DMEM/F12 media without FCS. DNA-PEI solution was added drop-wise to the 
cells, carefully spreading the solution over the entire surface of the well (i.e. 
each Eppendorf’s tube was added to each plate). 
 The dishes were incubated for 6 h in an incubator at 37 oC with 5 % CO2. 
 The PEI-containing media was replaced with DMEM/F12 media containing 10 
% FCS and the cells were incubated. 
 The supernatant containing viral particles on the cells was collected at 24, 48 
and 72 h, filtered through 0.2 µ filter and stored at 4 
o
C. After removing the 
media from the cells, carefully prewarmed fresh FCS-containing DMEM/F12 
medium was added. Care was taken to prevent the detachment of the cells from 
the surface while handling. 
 The cumulative supernatant was centrifuged in 30-40 kDa filter containing tubes 
at 3000 g for 15 min and the supernatant was collected (500-1000 µl) into 
separate labeled Eppendorf’s tubes. Samples were aliquoted and stored at -80 
o
C. 
Transduction of m-µOR SK-N-LO cells and selection of stable clones 
 40,000-50,000 m-µOR SK-N-LO cells/well were seeded into a 12 well plate 
with growth media containing 1:1 mixture of IMDM:HAM’S F12 supplemented 
with 10 % serum and 1 mg/ml G418. 
 The cells in each well were added with polybrene (final concentration 8 µg/ml). 
The plate was gently swirled to homogenize the medium while preventing the 
detachment of cells. 
 50 µl of lentiviral particles were added to the wells. The medium was gently 
distributed in the well.  
 Subsequently, the plates were centrifuged at 500 x g for 60 minutes and further 
incubated at 37 C in a humidified incubator in an atmosphere of 5 % CO2. 
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 6 to 8 hours post-infection polybrene containing medium was replaced with 
fresh growth medium. In order to raise the efficiency of transduction a second 
and a third infection round was carried out by adding new virus particles to the 
cells and spinning the plates again. Subsequently, the cells were incubated at 37 
C in a humidified incubator in an atmosphere of 5 % CO2. 
 After 24 to 48 hours the cell growth medium was replaced with the medium 
containing 1 µg/ml puromycin for selection. To monitor the efficiency of 
selection, one well was left uninfected and selected with the same amount of 
puromycin. 
 Selection against puromycin was maintained 10 to 14 days (i.e. stopped when no 
viable cells were visible in the uninfected control wells). 
 Cells were subsequently characterized for expression of PI3Kγ using SDS-
PAGE and subsequent immunoblotting. 
 
2.2.8 Preparation and culture of dorsal roort ganglia (DRGs) 
 DRG  medium: DMEM F12- Dulbecco’s modified Eagle Medium (Gibco) with 
1 mM Glutamine supplemented with 10 % FCS (heat inactivated) and 1 % 
Penicillin/Streptomycin 
 Mouse was anesthetized and killed by overdose of anaethesia. Spinal cord was 
dissected out, cleared off extra tissues and kept in ice cold DMEM/F12 medium. 
The spinal cord was cut into two halves along the longitudinal axis. The Dura, a 
quite solid and clear membrane lying between spinal cord and DRGs was 
removed carefully. DRGs were pulled out by holding the two long horns 
(neruites) protruding outside gently and kept in a small culture dish with 
DMEM/F12 medium. DRGs from all spinal levels were collected. The long 
horns and additional films of the DRG were cut by holding it with tweezers and 
smoothly cutting around like peeling. Subsequently, DRGs were transferred into 
new small culture dish with 2 ml of DMEM/F12 medium.  
 Collagenase (final concentration - 0.4 U/ml) was added to DRG containing 
culture dish and incubated at 37 
o
C for 45 min. After incubation, DRGs were 
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transferred to a 15 ml falcon tube with 2-3 ml of DMEM/F12 medium using a 
fire polished coated Pasture-pipette (coated with Sigmacote
®
).  
 After the DRGs were settled down at the bottom, the medium was aspirated out 
with Pasture-pipette. 1 ml trypsin was added to the tube with DRGs and 
incubated at 37 
o
C for 10 min. Following incubation, the DRGs were allowed to 
settle down. Subsequently, trypsin was aspirated out with Pasteur-pipette.  
 The DRGs were washed once with 2-3 ml of DMEM/F12 medium by aspirating 
the medium after the DRGs were settled down.  
 2 ml of DMEM/F12 medium was added to the tube. The DRGs were dissociated 
by beating the tube 10 times. The cells were allowed to settle down and the 
supernatant was collected into another falcon tube with Pasteur-pipette.  
 Addition of 2 ml of DMEM/F12 medium and the beating process was repeated 
(4 – 5 times) until no visible flocks appear in the supernatant and each time the 
supernatant was collected into another tube using Pasteur-pipette.  
 The collected supernatant was pipetted up and down with Pasteur-pipette for 10 
– 20 times carefully avoiding the air bubbles.  The tube was centrifuged at room 
temperature for 7 min at 1300 rpm in swinging bucket rotor (Heraus Megafuge 
1.0). 
 The supernatant was aspirated and 4 ml of DMEM/F12 medium supplemented 
with 10 % FCS and 1x Penicillin/Streptomycin was added to DRGs. The cells 
were resuspended by aspirating them using Pasteur-pipette. 
 The cells were centrifuged again at room temperature for 7 min at 1300 rpm. 
The supernatant was aspirated and added with sufficient new medium containing 
10 % FCS and 1x Pencillin/Streptomycin, to seed into either 12- well plates 
(20,000-30,000 cells/ well) for western blotting or into glass bottomed dishes 
coated with poly L-lysine (PLL)  for microscopy (around 15,000-20,000 
cells/dish). 
 
2.2.10 Immunocytochemistry 
The cells were washed with ice cold PBS. Added with 400 µl of ice cold Zamboni 
fixing solution and kept at room temperature for 30- 40 min. Zamboni fixing solution 
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was removed and the cells were washed with PB-buffer until the yellow color 
disappears (to wash off Zamboni fixing solution completely). The cells were 
permeabilized by incubating them with 1 ml of PB-buffer containing 0.1 % Triton X-
100 and 3 % normal goat serum for 2 h at room temparature. Then the primary antibody 
(1: 20) in PB-buffer containing 0.1 % Triton X-100 and 3 % normal goat serum was 
added to the cells and incubated overnight at 4 
o
C. The cells were washed with PB-
buffer for 4 times. Secondary antibody (Alexa 488-1:1000) in PB-buffer containing 0.1 
% Triton X-100 and 3 % normal goat serum was added to the cells. The dishes were 
kept in a dark room for 2 h at room temperature with gentle shaking. The cells were 
washed with PB-buffer for 4 times. The cells were visualized using laser scanning 
microscope (Zeiss Meta 510 Microscope) at 488 nm excitation wavelength with 40x 
optical zoom. 
 
2.2.11 Stimulation of DRGs 
Immediately following the collection, the DRGs were seeded in a 12 - well plate with 
DMEM/F12 media containing 10 % FCS. After 5-6 h of incubation at 37 
o
C in a 
humidified incubator in an atmosphere of 5 % CO2, the media was replaced with 
DMEM/F12 media without serum (starvation media). Following 10-12 h starvation 
period the cells were used for experiment. In a typical experiment, starved cells were 
preincubated with selected inhibitors or vehicle in serum free media for indicated time 
before stimulation with morphine. Immediately following stimulation, the cells were 
lysed in 100 µl of ice cold lysis buffer containing protease and phosphatase inhibitors.  
Incubated on ice for 10 min, then the cells were scraped and collected into Eppendorf’s 
tubes. The cell lysates were centrifuged at 14,000 rpm for 20 min at 4 
o
C. 90 µl of the 
cell lysate supernatants were added with 23 µl of 5x SDS-sample buffer. The samples 
were heated at 95 
o
C for 5 min. The samples were resolved by 10 % SDS-PAGE. 
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2.2.12 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
The prepared protein samples were resolved by SDS-PAGE. 10 % or 7.5 % 
polyacrylamide gels were prepared as mentioned below (Table. 2.3). Stacking gel was 
prepared on the separation gel. The protein samples were loaded in the slots made in 
collection gel. 
 
Table 2.3 Gel composition  
 
10 % 
Separation gel 
7.5 % 
Separation gel 
4 %  
Stacking gel 
Water 4.8 ml 8 ml 3.1 ml 
30 % Polyacrylamide 3.33 ml 5.3 ml 0.66 ml 
Separation gel buffer 1.9 ml 4 ml -- 
Collection gel buffer -- -- 1.25 ml 
20 % SDS 50 µl 80 µl 25 µl 
20 % APS 40 µl 40 µl 30 µl 
TEMED 4 µl 20 µl 2 µl 
 
The prestained protein marker was used to assess the molecular weight of the proteins. 
Proteins were resolved by applying a constant voltage of 110 V for 80-90 min using 1x 
PAGE buffer. 
 
2.2.12 Immunoblotting 
The proteins were transferred on to PVDF transfer membranes using a semi-dry transfer 
blotting system. Briefly, a sandwich was prepared by placing the gel and membrane 
between transfer buffer soaked wet Whatmann filter papers (3x) each at the top and 
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bottom, and applied an electric field to allow the transfer of proteins on to the 
membrane under constant current 1 mA/ cm
2 
for 2 h. Subsequently, the membranes 
were briefly kept in 1x TBS-T solution and then kept in blocking solution composed of 
2.5 % bovine serum albumin (BSA) in 1x TBS-T for 2 h.  The blocking solution was 
exchanged with respective primary antibody containing solution (2.5 % BSA in 1x 
TBS-T) and incubated overnight at 4 
o
C. Then the membranes were washed three times 
with 1x TBS-T and incubated for 1 h at room temperature with respective HRP-
conjugated secondary antibody in 5 % non-fat dried milk powder solution. Then the 
membranes were washed three times with 1x TBS-T. The blots were visualized in ECL 
solution for 1 min and images were captured on Luminescent Image Analyzer (LAS-
4000, FUJI FILM) for 1-10 min. Subsequently, the membranes were stripped using strip 
buffer at 56 
o
C for 30 min and blocked with 2.5 % BSA in 1 % TBS-T solution before 
probing with suitable primary antibodies and secondary antibodies for loading controls 
as mentioned above (reprobed). 
 
2.2.12 Statistical Analysis 
All data are given as mean ± SD of three to five individual experiments. To determine 
statistical significance of the described results, analysis of variance with Fischer’s LSD 
was performed. A p value of < 0.05 was considered as statistically significant. 
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3. Results 
3.1 Activation of AKT upon stimulation of µOR by morphine in       
SK-N-LO cells 
3.1.1 Expression of µOR in SK-N-LO cells  
We intended to study the involvement of PI3Kγ in µOR signaling. To facilitate such 
studies, we here describe the generation of a suitable cell culture model. SK-N-LO cells 
express PI3Kγ endogenously. Since the endogenous expression of µOR was 
undetectable, at least at protein level (Fig. 3.1A), plasmid pcDNA3.1 encoding HA-
tagged mouse µOR was transfected into SK-N-LO cells. 48 h after transfection the cells 
were selected using G418 for 2 weeks and propagated further. The expression of µOR 
in SK-N-LO cells was confirmed immunologically (Fig. 3.1). Human µOR expressing 
SK-N-LO cells served as positive control. In parallel, the expression of PI3Kγ was 
demonstrated in Fig. 3.2. This cell line with endogenous PI3Kγ and stably expressing 
µOR will be further referred to as m-µOR SK-N-LO. 
 
Fig. 3.1 Expression of µOR in SK-N-LO cells. Plasmid pcDNA3.1 encoding HA-tagged 
mouse µOR was transfected into SK-N-LO cells. Following selection, the cells were lsyed in 
RIPA buffer and glycosylated proteins were enriched using wheat germ lectin agarose beads. 
Proteins were eluted from the beads using SDS-sample buffer for 20 min at 60 oC. Supernatants 
from pull down samples were probed for β-actin. The samples were separated on a 7.5 % SDS-
PAGE and immunoblotted, A) with specific antibodies recognizing µOR and β-actin, B) with 
specific antibody recognizing µOR and after stripping redeveloped with specific antibody 
recognizing anti-HA. Human µOR expressing SK-N-LO cells served as positive control. 
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Fig. 3.2 Expression of PI3Kγ in m-µOR SK-N-LO cells. Whole cell lysates of m-µOR SK-N-
LO cells were lysed. The cell extracts were separated on a 10 % SDS-PAGE and 
immunoblotted with specific antibody recognizing N-terminus of catalytic subunit of PI3Kγ 
named p110γ. The blot was stripped and redeveloped with specific antibody recognizing α-
vinculin. 
 
3.1.2 Morphine activates AKT and ERK1/2 in m-µOR SK-N-LO cells 
To characterize the µOR mediated signaling activity, m-µOR SK-N-LO cells were 
stimulated with 10 µM morphine for indicated time periods (2.5 to 30 min) as shown in 
Fig. 3.3. After cell lysis, cell extracts were resolved by SDS-PAGE and immunoblotted. 
Treatment of cells with morphine evoked a transient activation protein kinase B (AKT). 
Maximum phosphorylation of AKT was observed at 2.5 min followed by a decline to 
reach control levels by 30 min. Phosphorylation of AKT at threonine 308 and serine 473 
sites were observed. In addition, morphine stimulation resulted in a strong activation of 
ERK1/2. The phosphorylation of ERK1/2 also followed similar time-dependent kinetics 
as of AKT in these cells. Hence, 2.5 min stimulation was considered for evaluation of 
the effect of different stimuli on morphine induced activation of AKT and ERK1/2 in 
these cells. Wherever higher phosphorylation of ERK1/2 was observed recognition of 
ERK1/2 by pan ERK1/2 antibody was impaired. So β-actin was probed for as an 
additional control. 
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Fig. 3.3 Morphine activates AKT and ERK1/2 in m-µOR SK-N-LO cells.  m-µOR SK-N-
LO cells were treated with 10 µM morphine for indicated time periods. Subsequently, whole 
cell lysates were separated on 10 % SDS-PAGE and immunoblotted with specific antibodies 
recognizing phosphorylated AKT serine 473 and phosphorylated ERK1/2. The blots were 
stripped and redeveloped with specific antibodies recognizing phosphorylated AKT threonine 
308 and total ERK1/2. Then the bolts were stripped again and redeveloped with specific 
antibodies recognizing total AKT and β-actin. 
 
3.1.3 Involvement of µOR and PI3Ks in morphine induced AKT and 
ERK1/2 activation  
We asked questions i) whether the morphine induced activation of AKT and ERK1/2 is 
mediated via µOR? Does it involve PI3Ks? In order to address these questions, m-µOR 
SK-N-LO cells were preincubated overnight with 100 ng/ml pertussis toxin (PTX), a Gi 
subtype of GPCR inhibitor, before being stimulated with 10 µM morphine for 2.5 min. 
Pretreatment with PTX blocked the morphine stimulated phosphorylation of AKT at 
sites threonine 308 and serine 473. In addition, inhibition of the morphine induced 
phosphorylation of ERK1/2 was also observed with this pretreatment (Fig. 3.4).  
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Fig. 3.4 Involvement of µOR and PI3Ks in morphine induced AKT activation. m-µOR SK-
N-LO cells were preincubated with 10 µM naloxone (30 min) or 100 ng/ml pertussis toxin 
(overnight) or 100 nM wortmannin (Wm) (30 min) before being stimulated with 10 µM 
morphine for 2.5 min. Cells were lysed, whole cell extracts were resolved by 10 % SDS-PAGE 
and immunoblotted with specific antibodies recognizing phosphorylated AKT threonine 308, 
phosphorylated AKT serine 473, phosphorylated ERK1/2. Subsequently, the membranes were 
stripped and reprobed with specific antibodies recognizing total AKT and total ERK1/2. 
 
Similarly, preincubation of m-µOR SK-N-LO cells for 30 min with 10 µM naloxone, a 
specific µOR antagonist, inhibited the morphine induced phosphorylation of AKT at 
both sites and ERK1/2. In addition, m-µOR SK-N-LO cells were pretreated with 100 
nM wortmannin, a PI3K inhibitor, for 30 min before being stimulated with 10 µM 
morphine for 2.5 min. Pretreatment with wortmannin resulted in inhibition of 
phosphorylation of AKT at threonine 308 and serine 473 sites (Fig. 3.4). Morphine 
induced phosphorylation of ERK1/2 was also abolished by pretreatment with 
wortmannin. Taken together, these data indicate that morphine induced activation of 
AKT and ERK1/2 involved stimulation of Gi subtype of GPCRs, that the receptor was 
µOR and a pathway dependent on activation of PI3Ks. 
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3.2 Identification of PI3K isoforms involved in the activation of AKT 
by morphine 
3.2.1 Pharmacological approach 
In order to study PI3K selectivity for morphine induced activation of AKT, we here 
investigated the possible role of PI3Kγ in morphine induced activation of AKT via 
µOR. In a typical experiment, m-µOR SK-N-LO cells were preincubated with 100 nM 
AS605240, a specific PI3Kγ inhibitor, for 15 and 30 min prior to stimulation with 10 
µM morphine for 2.5 min. After the cell lysis, the extracts were resolved by SDS-PAGE 
and immunoblotted. Pretreatment with AS605240 – either for 15 or 30 min – resulted in 
nearly complete inhibition of phosphorylation of AKT. The phosphorylation at 
threonine 308 and serine 473 sites was inhibited (Fig. 3.5). At 100 nM concentration 
AS605240 selectively inhibited PI3Kγ. Hence, this observation confirms the 
involvement of PI3Kγ in activation of AKT by stimulation of µOR with morphine. 
Nevertheless, other PI3K isoforms could be involved in this signaling process.  
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Fig. 3.5 Involvement of PI3Kγ in morphine induced activation of AKT. A. m-µOR SK-N-
LO cells were preincubated with AS605240 for 15 or 30 min. Subsequently, the cells were 
stimulated with 10 µM morphine for 2.5 min. After cell lysis, cell extracts were subjected to 10 
% SDS-PAGE and immunoblotting with specific antibodies as described in Fig: 3.4. B, C. 
Densitometric analysis of the Fig. A and similar experiments showing the ratio of P-AKT 
threonine 308/total AKT. (B) or P-AKT serine 473/total AKT (C). The data represent mean ± 
SD, n=3. The responses of 30 min preincubation with AS605240 were used for quantification. * 
P<0.05 compared to morphine treatment, n=3. 
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Class IA PI3K members, namely – p110α, β and δ isoforms, attached to p85 regulatory 
subunits, were conventionally reported to be associated with receptor tyrosine kinases 
and proved to have major role in insulin, growth hormone mediated signaling implying 
on cell growth, adhesion, survival and proliferation (Vanhaesebroeck et al., 2010). We 
investigated the possibility of their involvement in morphine induced activation of AKT 
by means of pharmacological inhibition using isoform specific inhibitors. In this study 
we used the following inhibitors. 
 
 
 
In a typical experiment, the cells were preincubated with isoform selective inhibitor for 
30 min as shown in Table. 3.1 and then stimulated with 10 µM morphine for 2.5 min. 
After the cell lysis, the extracts were resolved by SDS-PAGE and immunoblotted. The 
activation of AKT was unaffected by pretreatment with either A66 or IC87114, as 
evidenced by the unaltered phosphorylation of AKT at threonine 308 and serine 473 
sites in response to morphine stimulation (Fig. 3.6). In contrast, pretreatment with the 
selective PI3Kγ inhibitor AS605240 inhibited the morphine induced  
Compound 
Isoform 
selectivity 
IC50 
Concentrations 
used 
A 66 S form P110α 30 nM 30 nM 
TGX221 P110β 20 nM 20 nM 
IC87114 P110δ 200 nM 200 nM 
AS605240 P110γ 100 nM 1, 10 µM 
Wortmannin PI3Ks 3 – 14 nM 100 nM 
Table. 3.1 PI3K Isoform specific inhibitors (Hawkins et al., 2006; Jamieson et al., 2011) 
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Fig. 3.6 Involvement of PI3Kβ in morphine induced activation of AKT. A. m-µOR SK-N-
LO cells were pretreated with one of the PI3K isoform specific or non-specific inhibitors 
followed by stimulation with 10 µM morphine for 2.5 min. 1 µM and 10 µM concentrations of 
AS605240 represent a & b, respectively. Cell lysis, cell extract preparation, Western blot 
analysis and probing with indicated specific antibodies were done as described in Fig. 3.4. B, C. 
Densitometric analysis of Fig. A and similar experiments showing the ratio of phosphorylated 
AKT threonine 308/total AKT (B) or phosphorylated AKT serine 473/total AKT (C). The data 
represent mean ± SD, n=3. Data were compared to cells treated with 1 µM AS605240 
pretreatment.*P<0.05 compared to morphine treatment. 
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activation of AKT in a dose-dependent manner as evidenced by the inhibition of 
phosphorylation at both the phosphorylation sites. In addition, pretreatment with 
TGX221 – selective PI3Kβ inhibitor – also inhibited the morphine induced 
phosphorylation of AKT. Nevertheless, these data demonstrated that the major 
contributor to morphine induced AKT activation was PI3Kγ. Abrogation of the activity 
of other PI3K isoforms – p110α and δ did not show any effect up on morphine induced 
phosphorylation of AKT. However, TGX221 might have an additional role in morphine 
induced activation of AKT. The phosphorylation of ERK1/2 was affected in a similar 
pattern as of phosphorylation of AKT. The higher concentration of AS605240 used was 
to compensate for the loss of effectiveness following repeated freeze-thaw cycles of the 
same aliquot of the stock solution. 
 
3.2.2 Genetic approach 
3.2.2.1 Knockdown of PI3Kγ in m-µOR SK-N-LO cells by shRNA 
To investigate the requirement of PI3Kγ in morphine induced activation of AKT, we 
used RNAi approach to suppress the expression of PI3Kγ in m-µOR SK-N-LO cells. m-
µOR SK-N-LO cells were transduced with lentiviral particles containing either non-
targeting control shRNA or targeting PI3Kγ plasmids encoding different shRNA genes 
(γ1, γ3 and γ5). Following 48 h of transduction, the cells were selected with puromycin 
and expanded further. The cells were lysed, whole cell lysates were subjected to SDS-
PAGE and immunoblotted to analyze the expression of PI3Kγ. Simultaneously, separate 
set of cells were processed to monitor the presence of µOR following viral transduction. 
As shown in Fig. 3.7A the cells expanded from γ3 and γ5 clones showed most effective 
suppression of PI3Kγ compared to control shRNA expressing cells. Cells derived from 
γ5 clone showed nearly 70 % suppression of PI3Kγ. These cells were used for further 
studies (Fig. 3.7B). Further, the presence of µOR was confirmed in the cells (non-
targeting control shRNA treated cells) following viral transduction (Fig: 3.7C). The cell 
line treated with non-targeting control shRNA (without knock down PI3Kγ) will be 
further referred to as Ctrl-m-µOR SK-N-LO cells. The cell line with knockdown of 
PI3Kγ will be further referred to as γ5-m-µOR SK-N-LO cells. The analyses were 
carried out with cell pools propagated for short periods to avoid clonal drifts.  
Results | 52 
 
 
 
 
 
Fig. 3.7 Knockdown of PI3Kγ in m-µOR SK-N-LO cells by shRNA. A. Whole cell lysates of 
m-µOR SK-N-LO cells treated with non-targeting control shRNA or one of the PI3Kγ specific 
shRNA were subjected to 10 % SDS-PGAE and immunoboltted with specific antibodies for 
PI3Kγ and vinculin. B. Densitometric analysis showing the ratio of p110 gamma (γ) /vinculin 
following treatment of m-µOR SK-N-LO cells with non-targeting control shRNA or γ5 (G5) 
PI3Kγ specific shRNA. Data represent mean ± SD, n=4. C. m-µOR SK-N-LO cells treated with 
non-targeting control shRNA or naive cells were lysed in RIPA buffer and glycosylated proteins 
were enriched using wheat germ lectin agarose beads. Proteins were eluted from the beads using 
SDS-sample buffer for 20 min at 60 oC, subjected to SDS-PGAE and immunoblotted with 
indicated specific antibodies as described Fig. 3.1B. 
 
 
Results | 53 
 
 
 
3.2.2.2 Effect of viral transduction on signaling activity m-µOR SK-N-LO 
cells 
At first, we tested whether the cells behave the same after undergoing viral transduction 
and selection process. To test this, we compared the responses of the Ctrl-m-µOR SK-
N-LO cells with that of m-µOR SK-N-LO cells to various stimuli. Expression of PI3Kγ 
in Ctrl-m-µOR SK-N-LO cells was comparable to that of m-µOR SK-N-LO cells (Fig. 
3.8). In both types of cells, morphine stimulation evoked activation of AKT and 
ERK1/2 as evidenced by the phosphorylation of AKT and ERK1/2 which was 
completely blocked by pretreatment (overnight) of cells with PTX (100 ng/ml). This 
suggests that the basic responses of the cells to morphine stimuli and the pathway of the 
activation of AKT and ERK1/2 were similar in shRNA treated as well as untreated 
cells.  
 
Fig. 3.8 Effect of viral transduction on signaling activity m-µOR SK-N-LO cells. Ctrl-m-
µOR SK-N-LO and m-µOR SK-N-LO cells were preincubated either with vehicle or 100 ng/ml 
PTX (overnight). Then the cells were stimulated with 10 µM morphine for 2.5 min. After cell 
lysis, cell extracts were subjected to 10 % SDS-PAGE and immunoboltted with specific 
antibodies recognizing p110γ, phosphorylated AKT threonine 308 and phosphorylated ERK1/2. 
Then the membranes were stripped and redeveloped with specific antibodies recognizing 
vinculin, total AKT and total ERK1/2.  
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3.2.2.3 Requirement of PI3Kγ for morphine induced activation of AKT and 
ERK1/2 
To test the requirement of PI3Kγ for morphine induced activation of AKT we 
stimulated the Ctrl-m-µOR SK-N-LO cells and γ5-m-µOR SK-N-LO cells with 10 µM 
morphine for 2.5 min. As expected, morphine stimulation elicited activation of AKT in 
Ctrl-m-µOR SK-N-LO cells but not in γ5-m-µOR SK-N-LO cells.  The phosphorylation 
of AKT at threonine 308 and serine 473 sites was significantly reduced in γ5-m-µOR 
SK-N-LO cells compared to Ctrl-m-µOR SK-N-LO cells (Fig. 3.9). This was in line 
with our earlier observation using pharmacological inhibitors. Moreover, morphine 
induced phosphorylation of ERK1/2 was abolished in γ5-m-µOR SK-N-LO cells in 
contrast to the Ctrl-m-µOR SK-N-LO cells. These data demonstrate that PI3Kγ was 
indeed required for the activation of AKT and ERK1/2 upon stimulation of µOR with 
morphine. The residual activation seen in case of γ5-m-µOR SK-N-LO cells could be 
due to the residual PI3Kγ as the maximum suppression observed was nearly 70 %. 
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Fig. 3.9 Requirement of PI3Kγ for morphine induced activation of AKT. A. Ctrl-m-µOR 
SK-N-LO cells (Ctrl shRNA) and γ5-m-µOR SK-N-LO cells (G5 shRNA) were stimulated with 
10 µM morphine for 2.5 min. After cell lysis, cell extracts were resolved by 10 % SDS-PAGE 
and immunoblotted with specific antibodies recognizing p110γ, phosphorylated AKT threonine 
308 and phosphorylated ERK1/2. Then the membranes were stripped and redeveloped with 
specific antibodies recognizing phosphorylated AKT serine 473 and β-actin. B. Densitometric 
analysis of Fig: A and similar experiments showing the ratio of phosphorylated AKT threonine 
308/total AKT. The data represent mean ± SD, n=5. *P<0.05 compared to morphine treatment 
of Ctrl-m-µOR SK-N-LO cells. C. Densitometric analysis of Fig: A and similar experiments 
showing the ratio of phosphorylated AKT serine 473/total AKT. The data represent mean ± SD, 
n=3. *P<0.05 compared to morphine treatment of Ctrl-m-µOR SK-N-LO cells. 
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3.3 Crosstalk between cAMP-AKT pathways: Functional interaction of 
PI3Kγ-PKA-PDE upon agonist stimulation of µOR 
PI3Kγ has protein kinase and lipid kinase activities which result in activation of 
ERK1/2 and AKT, respectively (Bondeva et al., 1998). Kinase-independent activities of 
PI3Kγ regulate intracellular cAMP levels in cardiomyocytes (Patrucco et al., 2004) by 
stimulatory interaction with PKA and PDE3B. In cardiomyocytes, the multiprotein 
complex of p110γ-PKA-PDE3B enhances the phosphodiesterase activity of PDE3B, 
leading to increased breakdown of cAMP, and inhibits lipid kinase activity of p110γ, 
leading to reduced production of PtdIns(3,4,5)P3 (Perino et al., 2011). These 
observations indicated a crosstalk between cAMP-AKT pathways in case of 
cardiomyocytes.  
In our earlier experiments, we observed that PI3Kγ was involved in morphine induced 
activation of AKT. In line with the observations in caridomyocytes, we asked whether 
or not a crosstalk between cAMP and AKT pathways exists in neuronal cells? If so does 
it requires PI3Kγ? 
In order to address this question we used two model systems. 
1) SK-N-LO cell culture system: At first we explored the existence of a crosstalk 
between cAMP-AKT pathways in m-µOR SK-N-LO cells. Subsequently, we 
investigated the requirement of PI3Kγ using the cell lines Ctrl-m-µOR SK-N-
LO (with PI3Kγ) and γ5-m-µOR SK-N-LO (with down regulated PI3Kγ) 
generated as described in section 3.2.2.1, and 
2) Primary neuronal cell culture system: We used dorsal root ganglion cells 
(DRGs) from wild type and PI3Kγ-/- mice for this purpose. Primary neuronal 
cells from mouse DRGs express µOR and PI3Kγ endogenously. Availability of 
knockout mice makes it an ideal model system to investigate the effects of 
presence and absence of PI3Kγ in µOR mediated signal transduction, although it 
poses considerable methodological challenge.  
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3.3.1 Investigations in SK-N-LO cell culture system 
3.3.1.1 Effect of forskolin on the activation of AKT by morphine 
Here, we investigated the effect of elevated intracellular cAMP levels on activation of 
AKT by morphine. In order to do this, m-µOR SK-N-LO cells were preincubated with 
10 µM forskolin for 15, 30 and 60 min prior to stimulation with 10 µM morphine for 
2.5 min. Forskolin activates adenylyl cyclase which in turn elevates the intracellular 
cAMP levels (Yu and Sadée, 1988) giving rise to increased levels of PKA. Forskolin 
pretreatment resulted in inhibition of morphine induced activation of AKT. The 
phosphorylation of AKT at both threonine 308 and serine 473 sites was inhibited at all 
time points tested (Fig. 3.10). Forskolin treatment for 2.5 min, per se, did not affect 
AKT phosphorylation. Furthermore, pretreatment with forskolin did not affect the 
phosphorylation of ERK1/2 induced by morphine in the same cells, at all the time points 
tested. 
 
Fig. 3.10 Forskolin inhibits the morphine induced activation of AKT. m-µOR SK-N-LO 
cells were preincubated with 10 µM forskolin for 15 or 30 or 60 min as indicated. Subsequently, 
the cells were stimulated with 10 µM morphine or 10 µM forskolin for 2.5 min as indicated. 
After cell lysis, cell extracts were resolved by 10 % SDS-PAGE and immunoblotted as 
described in Fig: 3.4. 
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3.3.1.2 Effect of IBMX on the activation of AKT by morphine 
Further we asked a question, whether elevation of intracellular cAMP resulting from 
inhibition of its breakdown by phosphodiesterases (PDEs) would have similar effect on 
morphine induced AKT phosphorylation? To test the effect of inhibition of PDEs on 
morphine induced activation of AKT, m-µOR SK-N-LO cells were pretreated with 500 
µM IBMX for 15, 30 and 60 min prior to stimulation with 10 µM morphine for 2.5 min. 
IBMX is a non-selective phosphodiesterase inhibitor which enhances the intracellular 
cAMP levels by inhibiting its hydrolysis by PDEs (Weston et al., 1997). Pretreatment 
with IBMX inhibited the morphine induced phosphorylation of AKT at the 
phosphorylation sites, threonine 308 and serine 473. This effect was observed with a 
preincubation time of 15 min and persisted until 60 min (Fig. 3.11). IBMX treatment for 
2.5 min, per se, did not have any effect on AKT phosphorylation. The phosphorylation 
of ERK1/2 was unaffected similar to the case of forskolin pretreatment. 
 
Fig. 3.11 IBMX inhibits morphine induced activation of AKT. m-µOR SK-N-LO cells were 
preincubated with 500 µM IBMX for 15 or 30 or 60 min as indicated. Subsequently, the cells 
were stimulated with 10 µM morphine or 500 µM IBMX for 2.5 min as indicated. After cell 
lysis cell extracts were resolved by 10 % SDS-PAGE and immunoblotted as described in Fig: 
3.4. 
 
In total, these data indicate that enhanced intracellular cAMP levels inhibited the 
activation of AKT upon stimulation of µOR with morphine and demonstrated the 
existence of crosstalk between cAMP and PI3K/AKT pathway in neuronal cells as 
exemplified for SK-N-LO cells. 
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3.3.1.3 Effect of H-89 on morphine induced activation of AKT  
PKA is one of the effector proteins through which cAMP elicits its functions (Netherton 
et al., 2007). We hypothesized that the effects of elevated intracellular cAMP on 
morphine induced activation of AKT might have been mediated by PKA. In order to 
investigate this, m-µOR SK-N-LO cells were preincubated with 10 µM H-89, PKA 
inhibitor (Reuveni et al., 2002), for 15 and 30 min, prior to stimulation with 10 µM 
morphine for 2.5 min. The pretreatment of cells with H-89 enhanced morphine induced 
activation of AKT. Interestingly, the inhibition of PKA enhanced the phosphorylation of 
AKT at threonine 308 site but not at serine 473 site, at all the time points tested (Fig. 
3.12). However, pretreatment of cells with H-89 did not alter the phosphorylation of 
ERK1/2 at all the time points tested. These data demonstrated that elevated cAMP 
levels indeed act via PKA to affect morphine induced activation of AKT. 
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Fig. 3.12 H-89 enhances the morphine induced activation of AKT. A. m-µOR SK-N-LO 
cells were preincubated with 10 µM H-89 for 15 or 30 min as indicated. Subsequently, the cells 
were stimulated with 10 µM morphine for 2.5 min as indicated. After cell lysis, cell extracts 
were resolved by 10 % SDS-PAGE and immunoblotted as described in Fig: 3.4. B, C. 
Densitometric analysis of Fig. A and similar experiments showing the ratio of phosphorylated 
AKT threonine 308/total AKT (B) or phosphorylated AKT serine 473/total AKT (C). The data 
represent mean ± SD, n=3. *P<0.05 compared to the sample with morphine treatment. The 
responses of 30 min pretreatment with H-89 were used for quantification. 
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3.3.1.4 Effect of viral transduction on signaling activity in m-µOR SK-N-LO 
cells 
Because we found that there is a crosstalk occurring between cAMP and AKT pathways 
in m-µOR SK-N-LO cells we further investigated the involvement of PI3Kγ in this 
crosstalk.  At first, we explored whether the behavior of the cells to various stimuli 
following viral transduction is same or not? To test this, we compared the responses of 
m-µOR SK-N-LO cells to that of Ctrl-m-µOR SK-N-LO cells following stimulation 
with various agents. When stimulated with 10 µM morphine for 2.5 min, m-µOR SK-N-
LO cells as well as Ctrl-m-µOR SK-N-LO cells, showed similar activation of AKT as 
evidenced by phosphorylation of AKT at threonine 308 (Fig. 3.13). Pretreatment with 
10 µM forskolin for 30 min abolished the morphine induced phosphorylation of AKT at 
threonine 308 in m-µOR SK-N-LO cells as well as in Ctrl-m-µOR SK-N-LO cells, in a 
similar manner. Furthermore, pretreatment with 10 µM H-89 for 30 min, enhanced 
morphine induced activation of AKT, in both cell types, as evidenced by enhanced 
phosphorylation of AKT at threonine 308 site. These data suggested that the viral 
transduction did not alter the responses of the m-µOR SK-N-LO cells to various stimuli. 
 
Fig. 3.13 Effect of viral transduction on signaling activity in m-µOR SK-N-LO cells. Ctrl-
m-µOR SK-N-LO cells and m-µOR SK-N-LO were (cells expressing non-targeting control 
shRNA or naive cells) were preincubated with 10 µM forskolin (30 min) or 10 µM H-89 (30 
min) as indicated. Subsequently, the cells were stimulated with 10 µM morphine for 2.5 min as 
indicated. After cell lysis, the lysates were subjected to SDS-PAGE and immunoblotted with 
specific antibodies as described in Fig. 3.9. 
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3.3.1.5 Role of PI3Kγ on the influence of cAMP/PKA signaling on morphine 
induced activation of AKT  
In order to investigate the involvement of PI3Kγ in the influence of altered cAMP/PKA 
levels on AKT activation, Ctrl-m-µOR SK-N-LO cells and γ5-m-µOR SK-N-LO 
(depleted for PI3Kγ as shown above) cells were stimulated with 10 µM morphine for 
2.5 min. Morphine stimulation induced activation of AKT and ERK1/2 in Ctrl-m-µOR 
SK-N-LO cells but not in γ5-m-µOR SK-N-LO cells suggesting the requirement of 
PI3Kγ for morphine induced activation of AKT. 
We investigated the role of PI3Kγ in the effect of IBMX on activation of AKT by 
morphine. In order to do this, Ctrl-m-µOR SK-N-LO cells and γ5-m-µOR SK-N-LO 
cells were preincubated with 500 µM IBMX before being stimulated with 10 µM 
morphine for 2.5 min. The morphine induced phosphorylation of AKT at threonine 308 
was significantly impaired in γ5-m-µOR SK-N-LO cells than that observed in Ctrl-m-
µOR SK-N-LO cells (Fig. 3.14). Similar to the data obtained from m-µOR SK-N-LO 
cells, pretreatment of cells with IBMX resulted in inhibition of AKT in Ctrl-m-µOR 
SK-N-LO cells and this effect was diminished in γ5-m-µOR SK-N-LO cells. 
Further, pretreatment with 10 µM forskolin for 30 min, abolished the AKT activation by 
morphine in Ctrl-m-µOR SK-N-LO cells which was absent in case of γ5-m-µOR SK-N-
LO cells as there was no activation seen, in first case. Inhibition of PKA, by 
pretreatment with 10 µM H-89 for 30 min, enhanced the morphine induced 
phosphorylation of AKT at threonine 308 site in Ctrl-m-µOR SK-N-LO cells which was 
significantly higher than that observed in γ5-m-µOR SK-N-LO cells (Fig. 3.15). The 
phosphorylation at serine 473 site was not enhanced by H-89 pretreatment in response 
to morphine stimulation in Ctrl-m-µOR SK-N-LO cells. This was in line with the earlier 
observations with m-µOR SK-N-LO cells. These data indicate the requirement of PI3Kγ 
for the crosstalk between cAMP and AKT pathways involving PKA as a cAMP effector 
protein in SK-N-LO cells. The residual activity observed in case of H-89 pretreatment 
of γ5-m-µOR SK-N-LO cells might be a result of residual PI3Kγ as the maximum 
suppression achieved was ~70 % in these cells compared to Ctrl-m-µOR SK-N-LO 
cells. Moreover, morphine induced phosphorylation of ERK1/2 was unaffected by 
pretreatment with either forskolin or H-89 in Ctrl-m-µOR SK-N-LO cells whereas γ5-
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m-µOR SK-N-LO cells did not show phosphorylation of ERK1/2 in response to 
morphine stimulation. 
 
Fig. 3.14: Effect of PI3Kγ on influence of IBMX on morphine induced activation of AKT. 
A. Ctrl-m-µOR SK-N-LO cells (Ctrl shRNA) and γ5-m-µOR SK-N-LO cells (G5 shRNA) were 
preincubated with 500 µM IBMX for 30 min as indicated. Subsequently, the cells were 
stimulated with 10 µM morphine for 2.5 min as indicated. After cell lysis, cell extracts were 
resolved by 10 % SDS-PAGE and immunoblotted with specific antibodies as described in Fig. 
3. 9. B. Densitometric analysis of Fig. A and similar experiments showing the ratio of 
phosphorylated AKT threonine 308/total AKT. The data represent mean ± SD, n=3. *P<0.05 
compared to morphine treatment of Ctrl-m-µOR SK-N-LO cells. 
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Fig. 3.15 Effect of PI3Kγ on the influence of cAMP/PKA signaling on morphine induced 
activation of AKT. A Ctrl-m-µOR SK-N-LO cells (Ctrl shRNA-in the legend) and γ5-m-µOR 
SK-N-LO cells (G5 shRNA-in the legend) were preincubated with 10 µM forskolin or 10 µM 
H-89 for 30 min as indicated. Subsequently, the cells were stimulated with 10 µM morphine for 
2.5 min as indicated. After cell lysis, cell extracts were resolved by 10 % SDS-PAGE and 
immunoblotted with specific antibodies as described in Fig. 3.9. B. Densitometric analysis of 
Fig. A and similar experiments showing the ratio of phosphorylated AKT threonine 308/total 
AKT. The data represent mean ± SD, n=5. *P<0.05 compared to morphine treatment of Ctrl-m-
µOR SK-N-LO cells. #P<0.05 compared to treatment of Ctrl-m-µOR SK-N-LO cells treated 
with H-89 and morphine. C. Densitometric analysis of Fig. A and similar experiments showing 
the ratio of phosphorylated AKT serine 473/total AKT. The data represent mean ± SD, n=3. 
*P<0.05 compared to morphine treatment of Ctrl-m-µOR SK-N-LO cells. 
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Elevation of intracellular cAMP levels by forskolin or IBMX inhibited the morphine 
induced activation of AKT in a PI3Kγ dependent way. In addition, enhancement in 
morphine induced activation of AKT by inhibition of PKA required PI3Kγ. Taken 
together, these data demonstrate the central role of PI3Kγ in the crosstalk between 
cAMP and AKT pathways.  Further, the data indicate the functional interaction among 
PI3Kγ, PKA and PDE regulating the lipid kinase activity of p110γ in SK-N-LO cells 
upon stimulation of µOR with morphine. 
 
3.3.2 Investigations in primary neuronal cell system 
3.3.2.1 Expression of µOR and PI3Kγ in mouse DRGs  
We conducted our investigations on the role of PI3Kγ in µOR mediated signaling and 
its possible involvement in orchestrating the crosstalk between cAMP-AKT pathways in 
primary cell culture of mouse DRG sensory neurons. At first we show that DRG 
neurons express µOR and PI3Kγ endogenously. Here, we show the expression of µOR 
in cultured DRG neurons and the expression of PI3Kγ in paraformaldehyde-fixed 
paraffin embedded sections of DRG neurons (Fig. 3.16).  
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Fig. 3.16 Expression of µOR and PI3Kγ in mouse DRG. A. Confocal laser 
immunoflouroscence microscopy of cultured mouse DRG neurons examining the 
immunoreactivity for flourecently labeled anti-MOR monoclonal antibody. B. 
Immunohistochemical stainings were performed on sections from paraformaldehyde-fixed and 
paraffin embedded DRG from wild type and PI3Kγ knockout mice with anti-PI3Kγ specific 
antibody, mouse IgG2a isotype control (courtesy: Dr. C. König). DRGs from wild type mouse 
showing immunoreactivity for PI3Kγ in morphological small diameter neurons compared to 
IgG2a control staining in PI3Kγ knockout mouse DRGs. 
 
3.3.2.2 Requirement of PI3Kγ for the effects of cAMP/PKA on morphine 
induced activation of AKT  
To elucidate the role of PI3Kγ in signaling activity of µOR, DRG neuronal cells from 
wild type and PI3Kγ knockout mice were stimulated with 10 µM morphine for 2.5 min. 
After cell lysis, cell extracts were subjected to SDS-PAGE and immunoblotted. The 
treatment with morphine evoked an activation of AKT as evidenced by phosphorylation 
at threonine 308 site in wild type cells but not in knockout cells (Fig. 3.17). Morphine 
stimulation also elicited a slight activation of ERK1/2 in wild type cells, although not 
appreciably, as evidenced by phosphorylation of ERK1/2. In case of knockout DRG 
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neuronal cells, induction of phosphorylation of ERK1/2 was not observed in response to 
morphine  
 
 
Fig. 3.17 Requirement of PI3Kγ for the influence of cAMP/PKA on activation of AKT 
upon stimulation of µOR with morphine. A. DRG neuronal cells from wild type and PI3Kγ 
knockout mice were preincubated (30 min) with either 10 µM forskolin or 10 µM H-89 as 
indicated. Subsequently, the cells were stimulated with 10 µM morphine for 2.5 min. After cell 
lysis, cell extracts were subjected to 10 % SDS-PAGE and immunoblotted with specific 
antibodies recognizing phosphorylated AKT threonine 308 and phosphorylated ERK1/2. Then 
the membranes were stripped and redeveloped with specific antibodies recognizing total AKT 
and total ERK1/2. B. Densitometric analysis of the Fig. A and similar experiments, showing the 
ratio of P-AKT threonine 308/total AKT. The data represents mean ± SD, n=3. *p <0.05 
compared to morphine treatment of wild type DRG cells. # p<0.05 compared to H-89 treatment 
of wild type DRG cells. 
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stimulation. Taken together these data indicate that morphine induced activation of 
AKT in DRG neuronal cells was mediated via PI3Kγ. 
Further, we investigated the functional interactions of PI3Kγ and PKA. i.e. the influence 
of PI3Kγ on the effects of cAMP on PI3K/AKT pathway in cultured DRG neuronal 
cells. In order to do this, DRG neuronal cells from wild type and knockout mice were 
preincubated with 10 µM forskolin for 30 min prior to stimulation with 10 µM 
morphine for 2.5 min. Pretreatment with forskolin inhibited the morphine induced 
activation of AKT in wild type cells as evidenced by inhibition of phosphorylation of 
AKT at threonine 308 (Fig. 3.17). In case of knockout cells, activation of AKT by 
morphine and inhibition by forskolin pretreatment was not observed. However, 
phosphorylation of ERK1/2 was unaffected by pretreatment with forskolin in case of the 
wild type cells but knockout cells showed a higher phosphorylation of ERK1/2 
compared to morphine treatment. 
cAMP elicits its cellular functions by tethering or binding to effector proteins like PKA 
or EPAC (Netherton et al., 2007). We hypothesized, that the effect of cAMP on AKT 
might have been mediated by PKA. In order to investigate this, DRG neuronal cells 
from wild type and knockout mice were preincubated with 10 µM H-89 (PKA inhibitor) 
for 30 min before stimulation with 10 µM morphine for 2.5 min. Interestingly, 
pretreatment with H-89 resulted in enhanced morphine induced activation of AKT in 
wild type cells compared to knockout cells, as evidenced by the enhanced morphine 
induced phosphorylation of AKT at threonine 308 site (Fig. 3.17). These data indicated 
that the effect of cAMP on AKT was mediated by PKA and PI3Kγ was essential for 
enhanced activation of AKT. However, the induction of phosphorylation of ERK1/2 
was unaffected by H-89 pretreatment in the wild type cells as well as knockout cells. 
Taken together, these data suggest that activation of adenylyl cyclase by forskolin, 
inhibition of PKA by H-89 altered lipid kinase activity of p110γ as measured by the 
phosphorylation of AKT at threonine 308 site that was activated upon stimulation of 
µOR by morphine. 
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4. Discussion  
4.1 Generation of model systems 
In order to facilitate elaborative studies to explore the mechanism of µOR signaling and 
the role of PI3Kγ in signaling pathways we needed a suitable and convenient model 
system. Thus SK-N-LO cells that express PI3Kγ endogenously were stably transfected 
with a plasmid encoding mouse µOR which will be referred to as m-µOR SK-N-LO. 
The stable production of µOR and PI3Kγ was confirmed in this cell line, subsequently. 
To study the function of PI3Kγ, RNAi mediated suppression of PI3Kγ was carried out. 
This was accomplished by transduction of m-µOR SK-N-LO cells with lentiviral 
particles containing non-targeting control shRNA and targeting PI3Kγ to generate two 
more cell lines, namely, Ctrl- m-µOR SK-N-LO and γ5 m-µOR SK-N-LO, with and 
without PI3Kγ, respectively. The synthesis of µOR and PI3Kγ was confirmed 
subsequently. In addition, we tested whether the viral transduction has any effect on the 
signaling activity of these cells. In our observations we found comparable levels of 
expression of µOR and PI3Kγ in m-µOR SK-N-LO cells and Ctrl m-µOR SK-N-LO 
cells i.e. before and following viral transduction. Moreover, the signaling activity 
initiated by these cells to various stimuli remained unchanged. Thus, these cell lines 
were a suitable tool to study the role of PI3Kγ in µOR mediated signal transduction. 
Expression of PI3Kγ in murine bone marrow derived neutrophils, macrophages was 
reported earlier (Hirsch et al., 2000b). Presence of PI3Kγ in cardiomyocytes (Patrucco 
et al., 2004) airway smooth muscle cells (Jiang et al., 2010) and mast cells (Bohnacker 
et al., 2009) was reported subsequently. Expression of PI3Kγ in mouse brain tissue 
(mRNA and protein) was reported recently (Kim et al., 2011). Here, we show the 
expression of PI3Kγ in DRG neurons from wild type mice but not PI3Kγ-/- knockout 
mice. In the mean time, Cunha et al., reported the expression of PI3Kγ in wild type 
mouse and rat DRG neurons but not in PI3Kγ-/- mice DRG neurons (Cunha et al., 2010).  
Xu, et al., reported the endogenous expression of µOR in cultured DRG neurons of rats 
(Xu et al., 2003). In addition, Becker et al., reported the co-expression of TRPV1 
(transient receptor potential vanilloid receptor-1) and µOR in cultured rat DRG neurons 
along with the induction of expression of µOR in DRG neurons of rats with CFA 
induced inflammation (Endres-Becker et al., 2007). In line with the literature data we 
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here show the expression of µOR in cultured mouse DRG neurons. Thus, we confirmed 
the endogenous expression of µOR and PI3Kγ in mouse DRG neurons.  
 
4.2 Activation of AKT by morphine 
AKT also known as PKB (protein kinase B) is a 57 kDa serine /threonine protein kinase 
that is activated upon by various cell surface receptor stimuli. Various agonists, like 
chemokines and growth hormones etc., stimulate GPCRs to activate AKT which then 
propagates the signals inside the cells. Thus, AKT serves as a signaling mediator for 
many cellular processes like cell survival, adhesion, migration and proliferation, 
apoptosis and pain relief. AKT contains PH domain which binds to PtdIns(3,4,5)P3/ 
PtdIns(4,5)P2 produced upon activation of PI3Ks and thus serves as a marker for PI3Ks 
activation by cell surface receptors (Vanhaesebroeck and Alessi, 2000). Bondeva et al., 
reported the activation of AKT by PI3Kγ elucidating the lipid kinase activity of p110γ 
differentiating itself from the protein kinase activity (Bondeva et al., 1998). Generally, 
activation of AKT is monitored by phosphorylation of AKT at threonine 308 residue 
located in the activation loop and serine 473 residue located in the C-terminal 
hydrophobic motif. Phosphorylation of AKT at threonine 308 site occurs via 
phosphoinositide–dependent kinase-1(PDK1) which is also a PH domain containing 
protein kinase that binds to PtdIns(3,4,5)P3. But PDK1 dependent phosphorylation of 
AKT is strictly dependent on prior binding of PtdIns(3,4,5)P3 to AKT at PH domain 
because only then it relives the PH domain mediated inhibition to make the threonine 
308 in the activation loop available for phosphorylation (McManus et al., 2004; 
Hawkins et al., 2006). Moreover, downstream protein kinase activity of AKT is best 
represented by the phosphorylation at threonine 308 site rather than at serine 473 site: 
Phosphorylation of downstream substrates of AKT kinase PRAS40, TSC2 which are 
important regulatory components of mTOR complex and TBC1D4 which is a Rab 
GTPase activating protein with a role in regulation of glucose metabolism, are best 
correlated with phosphorylation of AKT at threonine 308 than at serine 473 in samples 
of early-stage non-small cell lung carcinoma (NSCLC) (Vincent et al., 2011). Further, a 
better correlation was established between phosphorylation of AKT at threonine 308 
site (but not serine 473 site) and poor prognosis in NSCLC and acute myeloid leukemia 
(Tsurutani et al., 2007; Gallay et al., 2009). Hence, in our studies, we monitored 
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phosphorylation of AKT at threonine 308 site preferentially over phosphorylation at 
serine 473 site. 
Morphine which is an agonist at µOR stimulates survival signals by activation of AKT, 
p70S6k and 4E-BP1 in Chinese Hamster ovary cells expressing µOR where the authors 
reported the phosphorylation of AKT at serine 473 site (Polakiewicz et al., 1998). In 
agreement with these data, in our studies we found that stimulation of m-µOR SK-N-
LO cells with morphine resulted in activation of AKT as monitored by phosphorylation 
of AKT at serine 473 site. In addition, we observed the phosphorylation of AKT at 
threonine 308 site in response to morphine stimulation in these cells. Phosphorylation at 
both sites followed similar kinetics, peaking at 2.5 min with decline to reach control 
levels by 30 min. Polcakwiz et al., reported that the activation of AKT by morphine 
occurs via a pathway sensitive to Gi subtype of GPCR inactivator, pertussis toxin 
(PTX), µOR specific antagonist, naloxone and pan PI3Ks inhibitor, wortmannin (Wm) 
in Chinese Hamster ovary cells expressing µOR (Polakiewicz et al., 1998). Similar to 
these data preincubation of m-µOR SK-N-LO cells with PTX, naloxone and Wm 
inhibited the morphine induced activation of AKT as evidenced by inhibition of 
phosphorylation of AKT at threonine 308 and serine 473 sites. This indicated that 
morphine induced activation of AKT in m-µOR SK-N-LO cells occurred via µOR 
which is a Gi type of GPCR and was mediated by the activation of PI3K. 
A similar report about the involvement of PI3Kγ in Gi subtype of GPCR signaling was 
from our laboratory proving the activation of MAPK by stimulation of m2 receptors 
over expressed in COS-7 cells with carbachol (Lopez-Ilasaca et al., 1997). There are 
reports about the involvement of class IA PI3K isoform, PI3Kβ, in GPCR mediated 
activation of AKT. Cardiomyocytes from PI3Kβ knockout mice show inhibition of 
AKT compared to their wild type counterparts upon stimulation of β-adrenergic 
receptor with isoproterenol (Perino et al., 2011). In macrophages, PI3Kβ along with 
PI3Kγ contributed to the activation of AKT in response to complement fragment 5a 
(C5a) stimulation as evidenced by blockade of phosphorylation of AKT by 
preincubation of cells with isoform specific small molecule inhibitors (Guillermet-
Guibert et al., 2008). In agreement with these literature data, our data indicated that 
PI3Kγ and PI3Kβ are the PI3K isoforms involved in mediation of morphine induced 
activation of AKT in m-µOR SK-N-LO cells. Pharmacological inhibition of PI3Kγ and 
β by preincubation of m-µOR SK-N-LO cells with 100 nM AS605240 and TGX 221, 
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selective inhibitors of PI3Kγ and β, respectively, inhibited the morphine induced 
phosphorylation of AKT at threonine 308 and serine 473 sites. Pharmacological 
inhibition of PI3Kα and δ by pretreatment with A66 and IC87114 - PI3Kα and δ 
selective inhibitors, respectively, did not interfere with morphine induced activation of 
AKT in m-µOR SK-N-LO cells. This is consistent with the literature reports indicating 
their involvement in receptor tyrosine kinase mediated signaling rather than GPCR 
mediated signaling (Vanhaesebroeck et al., 2010). 
Morphine induced activation of AKT as evidenced by the phosphorylation of AKT at 
threonine 308 site and its inhibition by PTX pretreatment was observed in Ctrl-m-µOR 
SK-N-LO cells expressing non-targeting shRNA control, similar to the case of m-µOR 
SK-N-LO cells suggesting the unaltered signaling activity of the cells following viral 
transduction. In addition, γ5-m-µOR SK-N-LO PI3Kγ knock down cells showed 
significantly reduced activation of AKT compared to Ctrl-m-µOR SK-N-LO cells in 
response to morphine stimulation. Phosphorylation of AKT at threonine 308 and serine 
473 sites was significantly inhibited by depletion of PI3Kγ suggesting the requirement 
of PI3Kγ for morphine induced activation of AKT. 
In similar lines, we observed the phosphorylation of AKT at threonine 308 site 
following stimulation of wild type cultured DRG neurons with morphine which was not 
observed in PI3Kγ-/- DRGs in our studies, suggesting the requirement of PI3Kγ for 
morphine induced activation of AKT. Cunha et al., showed stimulation of cultured DRG 
neurons with morphine induced activation of AKT as shown by phosphorylation at 
serine 473 site which was mediated by µOR. This activation of AKT was not observed 
in DRG neurons that lack PI3Kγ (Cunha et al., 2010).  
 
4.3 Activation of ERK1/2 by morphine 
Earlier reports suggested the activation of MAPK by stimulation of µOR over expressed 
in Chinese hamster ovary cells. Activation peaked at 4 to 8 min and maintained till 1 h 
(Li and Chang, 1996). In line with this, Rozenfeld et al., reported the activation of 
ERK1/2 upon stimulation of Chinese hamster ovary cells expressing µOR with 
DAMGO (Rozenfeld and Devi, 2007). In agreement with these data, we found that 
morphine stimulation induced a strong phosphorylation of ERK1/2 in m-µOR SK-N-LO 
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cells but differing from the reported observations followed a time-course with strong 
and maximum activation at 2.5 min with a decline to reach control levels by 30 min. 
The time-course of morphine induced phosphorylation of ERK1/2 followed similar 
kinetics to that of activation of AKT in m-µOR SK-N-LO cells. Further, morphine 
induced phosphorylation of ERK1/2 in m-µOR SK-N-LO cells was inhibited by PTX, 
naloxone and Wm pretreatment suggesting that it was mediated by Gi subtype of 
GPCR. These data indicated that the µOR mediated activation of ERK1/2 by morphine 
was dependent on activation of PI3K which was in agreement with the observation from 
earlier reports.  
Involvement of PI3Kγ in GPCR mediated activation of ERK1/2 representing the protein 
kinase activity of p110γ was reported earlier from our laboratory (Lopez-Ilasaca et al., 
1997). Similar to this data, morphine induced ERK1/2 activation was mediated by 
PI3Kγ in m-µOR SK-N-LO cells. Pharmacological inhibition of PI3Kγ, by AS605240 
inhibited the phosphorylation of ERK1/2 in a dose-dependent manner. Pharmacological 
inhibition of PI3Kα and δ did not interfere with the phosphorylation of ERK1/2. 
Pharmacological inhibition of PI3Kβ by preincubation of m-µOR SK-N-LO cells with 
TGX221 inhibited the phosphorylation of ERK1/2 suggesting an additional role for this 
class IA PI3K isoform in µOR signaling as in the case of activation of AKT. This was 
in agreement with recent reports indicating a role for PI3Kβ in GPCR mediated 
signaling as in the case of AKT activation.  
Morphine induced activation of ERK1/2 as evidenced by the phosphorylation of 
ERK1/2 and its inhibition by PTX pretreatment was observed in Ctrl-m-µOR SK-N-LO 
cells expressing non-targeting shRNA control, similar to the case of m-µOR SK-N-LO 
cells suggesting the unaltered signaling activity of the cells following viral transduction. 
In addition, γ5-m-µOR SK-N-LO PI3Kγ down regulated cells showed almost complete 
inhibition of activation of ERK1/2 compared to Ctrl-m-µOR SK-N-LO cells in response 
to morphine stimulation, suggesting the requirement of PI3Kγ for morphine induced 
activation of ERK1/2.  
However, we did not observe appreciable levels of activation of ERK1/2 upon morphine 
stimulation of wild type DRG neurons compared to PI3Kγ-/- DRGs. Moreover, forskolin 
and H-89 pretreatment did not alter this effect in wild type DRGs. 
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4.4 Central role of PI3Kγ in crosstalk between cAMP-AKT pathways 
 
 
Fig. 4.1 Schematic representation of elucidation of the role of PI3Kγ in crosstalk between 
cAMP and AKT pathways. Role of PI3Kγ in morphine induced activation of AKT was 
investigated by pharmacological inhibition and genetic knockdown of PI3Kγ. Forskolin, IBMX 
elevates cAMP levels which in turn affected morphine induced activation of AKT. H-89 inhibits 
PKA which subsequently affected morphine induced activation of AKT, illustrating the 
crosstalk between cAMP-AKT pathways. Effects of forskolin, IBMX and H-89 on morphine 
induced activation of AKT in presence and absence of PI3Kγ were investigated to elucidate the 
role of PI3Kγ in the crosstalk between cAMP/PKA – PI3K/AKT pathways. 
 
Because we observed that PI3Kγ mediates morphine induced activation of AKT we 
further explored the crosstalk between cAMP-AKT pathways and the role PI3Kγ plays 
in this crosstalk. In our cell culture model, we altered the intracellular cAMP levels 
either by activation of adenylyl cyclase or by inhibition of phosphodiesterases that 
catalyze the hydrolysis of cAMP and monitored the effects on morphine induced 
activation of AKT. Preincubation of m-µOR SK-N-LO cells with either forskolin, 
indirect activator of cAMP or IBMX, a non specific phosphodiesterase (PDEs) 
inhibitor, inhibited the morphine induced activation of AKT as evidenced by the 
inhibition of phosphorylation of AKT at threonine 308 and serine 473 sites. In similar 
lines, pretreatment of m-µOR SK-N-LO cells with H-89, PKA inhibitor, enhanced 
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morphine induced activation of AKT. Interestingly, the phosphorylation at threonine 
308 site but not at the serine 473 site was enhanced significantly by the inhibition of 
PKA in these cells. This novel finding demonstrated that the H-89 effect was mediated 
indeed via PI3Ks. This observation was supported by earlier reported observations 
where staurosporine, a potent PDK1 inhibitor, attenuated the activation of AKT in 
cultured HEK293 cells stimulated by insulin which is manifested as inhibition of 
phosphorylation at threonine 308 site with no effect on phosphorylation of serine 473 
site, which is a mTORC2 effector protein in many cell types (Hill et al., 2001; Hresko 
and Mueckler, 2005). Moreover, preincubation of m-µOR SK-N-LO cells with either 
forskolin, IBMX or H-89 did not alter morphine induced phosphorylation of ERK1/2 
suggesting that the protein kinase activity of p110γ was not affected.  Taken together, 
these data indicated a crosstalk between cAMP-AKT pathways arising out of functional 
interaction among PI3Kγ-PKA-PDE resulting in alteration of lipid kinase activity of 
p110γ in neuronal cells as exemplified by SK-N-LO cells. Interestingly, only the lipid 
kinase activity of p110γ was affected by these interactions but not the protein kinase 
activity as measured by the phosphorylation of AKT at threonine 308. However, 
elevation of cAMP by forskolin or IBMX resulted in inhibition of phosphorylation of 
AKT at both the phosphorylation sites but inhibition of PKA resulted in enhancement of 
phosphorylation of threonine 308 site only. The reason for such difference needs further 
investigations. 
In similar lines, pretreatment of Ctrl-m-µOR SK-N-LO cells expressing non-targeting 
shRNA control with forskolin or IBMX inhibited the morphine induced 
phosphorylation of AKT at threonine 308 and serine 473 sites similar to m-µOR SK-N-
LO cells. But as the morphine induced activation of AKT was not observed in case of 
γ5-m-µOR SK-N-LO PI3Kγ depleted cells further inhibition by forskolin could not be 
observed. However, the effect of IBMX pretreatment on morphine induced AKT 
activation was diminished in case of γ5-m-µOR SK-N-LO cells compared to Ctrl-m-
µOR SK-N-LO cells. Furthermore, H-89 pretreatment of Ctrl-m-µOR SK-N-LO cells 
enhanced morphine induced phosphorylation of AKT at threonine 308 site but not at 
serine 473 site similar to the case of m-µOR SK-N-LO cells whereas γ5-m-µOR SK-N-
LO cells showed significantly reduced enhancement of morphine induced 
phosphorylation of AKT. Taken together, these data indicates the functional interaction 
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between PI3Kγ, PKA and PDE in neuronal cells as exemplified by SK-N-LO cells and 
the requirement of PI3Kγ for the crosstalk between cAMP/PKA-PI3K/AKT pathways. 
In our observations, elevation of intracellular cAMP levels by forskolin pretreatment 
resulted in inhibition of morphine induced phosphorylation of AKT in cultured DRG 
neurons. In addition, inhibition of PKA by H-89 pretreatment enhanced the morphine 
induced activation of AKT in cultured DRG neurons. These data suggest a crosstalk 
between cAMP/PKA and PI3K/AKT pathways. Furthermore, altered morphine induced 
phosphorylation of AKT by forskolin and H-89 was observed in case of DRG neurons 
from wild type mice but not PI3Kγ-/- mice. This novel observation indicated the 
requirement of PI3Kγ for PKA mediated effects on AKT resulting in crosstalk between 
cAMP and AKT pathways. Moreover, the altered PKA levels did not affect the 
phosphorylation of ERK1/2. 
The direct interaction of PI3Kγ with PKCα regulating the fMLP induced production of 
reactive oxygen species in neutrophils was reported from our laboratory earlier 
(Lehmann et al., 2009). Perino et al., reported the functional and physical interaction 
between PI3Kγ and PKA earlier. In cardiomyocytes PKA binds to a site on N-terminal 
region of p110γ orchestrating the multiprotein complex containing regulatory subunits 
p84/87-p110γ-PKA-PDE3B. The association of PKA with p110γ leads to 
phosphorylation of p110γ and PDE3B by PKA. Further, the phosphodiesterase activity 
of PDE3B will be enhanced resulting in breakdown of cAMP negatively affecting 
myocardial contractility. Binding of regulatory subunits to the p110γ following PKA 
binding is essential for this stimulation of PDE activity of PDE3B (Perino et al., 2011). 
In cardiomyocytes lacking PI3Kγ higher cAMP levels were observed which was due to 
defective PDE3B functioning. Consequently, PI3Kγ-/- mice developed rapid and fatal 
cardiomyopathy in response to cardiac pressure overload induced by transverse aortic 
constriction (TAC). Interestingly, PI3KγKD/KD mice, unlike PI3Kγ-/- mice, showed 
similar adaptive responses to that of control mice indicating that PI3Kγ has kinase-
indepenednt functions (Patrucco et al., 2004). 
In addition, the lipid kinase activity of PI3Kγ will be affected negatively by PKA 
mediated phosphorylation of p110γ. In case of cardiomyocytes, agonist stimulation of 
β-adrenergic receptor, which is a Gs coupled GPCR, increases the intracellular cAMP 
levels giving rise to elevated PKA levels which then phosphorylate p110γ inhibiting its 
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lipid kinase activity. Under such circumstances, pretreatment with H-89 restored the 
lipid kinase activity of p110γ following isoproterenol treatment as evidenced by the 
increased PtdIns(3, 4, 5)P3 production (Perino et al., 2011). However, it was not shown 
whether this was reflected down-stream of PtdIns(3, 4, 5)P3 i.e. at the level of 
phosphorylation of AKT which is a bona-fide effector protein containing PH domain 
that is activated upon by PtdIns(3, 4, 5)P3 and a marker for PI3Kγ lipid kinase activity 
downstream of PtdIns(3, 4, 5)P3 (Bondeva et al., 1998).  
In our experiments, absence of PKA mediated inhibition, brought about by pretreatment 
with H-89, might have resulted in enhanced lipid kinase activity of p110γ causing 
enhanced morphine induced phosphorylation of AKT at threonine 308 in case of SK-N-
LO cells and DRG neurons with PI3Kγ, but not in those with down regulated PI3Kγ or 
without PI3Kγ. This might have downstream functional consequences.  
Capsaicin induces activation of AKT and ERK1/2 in a PI3K dependent way in cultured 
rat DRG neurons. In a model of rat hind paw inflammation, intradermal injection of 
capsaicin produced heat hyperalgesia which was inhibited by pretreatment with 
wortmannin (PI3K  inhibitor) or PD98059 or U0126 (MEK/ERK inhibitors). However, 
the early induction of hyperalgesia was inhibited only by inhibition of PI3K but not by 
the inhibition of MEK suggesting that the early induction of hyperalgesia is independent 
of ERK activation (Zhuang et al., 2004). Morphine induces peripheral analgesia in a 
PGE2 induced inflammatory pain model by activating AKT in a PI3Kγ dependent way 
which then activates nNOS (neuronal nitric oxide synthase) and NO (nitric oxide) 
production in DRG neurons resulting in increased KATP currents hyperpolarizing the 
nonciceptive neurons (Cunha et al., 2010). Morphine inhibits TRPV1 currents induced 
by capsaicin by acting on µOR and in a cAMP/PKA dependent pathway. In vivo 
manifestation of this was inhibition of capsaicin induced inflammatory pain (Endres-
Becker et al., 2007). Taken together, these data illustrate that morphine induced 
peripheral analgesia involves the two signaling pathways cAMP pathway as well as 
AKT pathway. Our observations showed the effects of cAMP on AKT upon stimulation 
of µOR with morphine in SK-N-LO cells and cultured mouse DRG neurons. Hence, our 
observation that H-89 pretreatment enhanced morphine induced phopshorylation of 
AKT i.e. at a level down-stream of PtdIns(3, 4, 5)P3 might indicate that this interaction 
of PI3Kγ-PKA would have functional implications downstream of AKT leading to 
peripheral analgesia induced by morphine. 
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In summary, our observations from SK-N-LO cell system and complementary data from 
primary neuronal cell system suggest that PI3Kγ mediates morphine induced activation 
of AKT and acts as a nodal point organizing a crosstalk between cAMP and AKT 
pathways in these model systems. This is in line with recent investigations in 
cardiomyocytes (Patrucco et al., 2004; Perino et al., 2011). Taken together, this is 
represented as a model in Fig. 4.2, wherein PI3Kγ functions as a nodal point in the 
signal transduction by µOR upon agonist stimulation.  
 
 
Fig. 4.2 Proposed model of interaction of p84/87, p110γ, PKA and PDE  
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5. Zusammenfassung  
Phosphoinositide-3-kinase (PI3Ks) sind Enzyme, welche die Phosphorylierung der 3’-
Position von Inositolen katalysieren. Durch diese Aktivität sind sie an der Regulation 
von vielen zellulären Prozessen wie Proliferation, Überleben und Migration beteiligt. 
Während die Isoformen PI3Kα, β und PI3Kδ in der Signaltransduktion von Rezeptor-
Tyrosin-Kinasen beteiligt sind, regulieren die Isoformen PI3Kβ and PI3Kγ Signalwege, 
die über G-Protein-gekoppelte–Rezeptoren (GPCR) vermittelt werden.  
Das Rezeptorprotein µOR ist ein GPCR, welches sich mit Gi-Proteinen assoziiert. 
Morphin ist eine opioide analgetische Droge, die als Agonist von µOR zur 
Schmerzlinderung eingesetzt wird. Durch permanente Behandlung dieses Agonisten 
kommt es zur Desensibilisierung des µOR und zu zellulären Anpassungen, welche die 
Wirkung dieses Agonisten einschränken. Die molekularen Mechanismen, die zu dieser 
Desensibilisierung führen sind noch nicht aufgeklärt. 
Um die Funktion von PI3Kγ bei der µOR-vermittelten Signaltransduktion weitergehend 
beschreiben zu können, wurden geeignete Modell-Zellsysteme generiert. Die humane 
Neuroblastom-Zelllinie SK-N-LO, die endogen PI3Kγ exprimiert, wurde mit einem 
µOR-kodierenden Plasmid transfiziert und stabil µOR-produzierende m-µOR-SK-N-
LO-Zellen propagiert. Durch stabile lentivirale Transduktion von shRNA wurde in 
diesen Zellen die Expression von PI3Kγ stabil unterdrückt. Die generierte Zelllinie γ5-
m-µOR-SK-N-LO zeigt ein um 70% vermindertes Niveau von PI3Kγ im Vergleich zu 
der mit einer Kontroll-shRNA transduzierten Zelllinie Ctrl-m-µOR-SK-N-LO. 
Die Stimulation von m-µOR-SK-N-LO mit Morphin resultierte in einer Aktivierung der 
Signalproteine AKT und ERK1/2. Das Maximum der Stimulation wurde 2,5 min nach 
Morphin-Zugabe erreicht. Die Aktivierung von AKT wurde durch die Phosphorylierung 
der Aminosäure-Reste Serin473 und Threonin308 demonstriert. Die Behandlung der 
Zellen mit dem Gi-Aktivator Pertussis Toxin, dem spezifischen m-µOR-Agonisten 
Naloxon bzw. dem pan-spezifischen PI3K-Inhibitor Wortmannin hemmte die Morphin-
induzierte Aktivierung von AKT. Daraus lässt sich schlussfolgern, dass PI3K-Proteine 
bei der Aktivierung von µOR beteiligt sind. 
Die pharmakologische Hemmung von PI3Kβ oder PI3Kγ blockierte die Morphin-
induzierte Aktivierung von AKT in m-µOR-SK-N-LO-Zellen. Demgegenüber hatte in 
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diesen Zellen die pharmakologische Hemmung von PI3Kα oder PI3Kδ keinen Einfluss 
auf die Morphin-vermittelte Aktivierung von AKT. Die PI3Kγ-Knock down Zelllinie 
γ5-m-µOR-SK-N-LO zeigte eine signifikant reduzierte Phosphorylierung von AKT, 
woraus sich schlussfolgern lässt, dass PI3Kγ für die Morphin-vermittelte Aktivierung 
von AKT benötigt wird.  
Forskolin und IBMX sind Agenzien, welche das intrazelluläre Niveau von cAMP 
erhöhen. Die Vorinkubation von m-µOR-SK-N-LO-Zellen mit diesen Substanzen 
inhibierte die Morphin-vermittelte Aktivierung von AKT. Die Hemmung der 
Proteinkinase A (PKA) mit H-89 erhöhte die Morphin-induzierte Threonin308-
Phosphorylierung von AKT. Diese Ergebnisse demonstrieren den cross talk der cAMP- 
und µOR-vermittelten Signaltransduktionswege. Während die Vorbehandlung von Ctrl-
m-µOR-SK-N-LO-Zellen zu einer signifikanten Erhöhung der Morphin-vermittelten 
AKT-Aktivierung führte, war diese Stimulierung in PI3Kγ-depletierten γ5-m-µOR-SK-
N-LO-Zellen drastisch eingeschränkt. Daraus lässt sich schlussfolgern, dass PI3Kγ am 
cross talk von cAMP und AKT-vermittelten Signalwegen beteiligt ist. 
Durch die Phosphorylierung von AKT am Threonin-Rest 308 wurde in dieser Arbeit 
erstmalig gezeigt, dass Morphin AKT aktiviert. Diese Signalaktivität wurde als Marker 
eingesetzt, um den cross talk zwischen cAMP- und AKT-vermittelten Signalwegen 
weitergehend zu untersuchen. Die Erhöhung der AKT-Stimulierung durch die 
Hemmung von PKA über H-89 und Abhängigkeit dieser Stimulierung durch PI3Kγ 
liefern neue Einblick in die Regulation dieser Signalprozesse. Da AKT über PI3Kγ 
aktiviert wird, lässt sich spekulieren, dass die Hemmung von PKA in einer Erhöhung der 
spezifischen Lipid-Kinase-Aktivität resultiert. 
Weitergehend wurde der Zusammenhang zwischen cAMP- und AKT-vermittelten 
Signalwegen in primären neuronalen Zellen untersucht, welche von PI3Kγ-Wildtyp und 
PI3Kγ-Knock out Mäusen isoliert wurden. Die Morphin-induzierte Aktivierung von 
AKT wurde in kultivierten DRG (dorsal root ganglia)-Wildtyp-Neuronen nachgewiesen. 
In DRG-Zellen von PI3Kγ-Knock out-Mäusen fand diese Aktivierung nicht statt. 
Außerdem führte die Vorbehandlung von DRG in Wildtyp-Zellen zu einer Inhibierung 
der Morphin-induzierten AKT-Aktivierung, die nicht in DRG-Knock out-Zellen 
beobachtet werden konnte. Die Hemmung von PKA durch H-89 resultierte in einer 
Stimulierung der Morphin-induzierten Aktivierung von AKT in Wildtyp-DRG, jedoch 
nicht in PI3Kγ-Knock out-DRG. 
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6. Summary 
Phosphoinositide-3-kinases (PI3Ks) are enzymes that catalyze the phosphorylation of 3 
position of the inositol ring of the phosphoinositol lipids. By this way they are 
implicated in many cellular processes like cell cycle progression, cell growth, survival 
and migration. Whereas PI3Kα, β and PI3Kδ isoforms were involved in receptor 
tyrosine kinase signaling, PI3Kβ and PI3Kγ are the PI3K isoforms involved in GPCR 
mediated signaling.  
µOR is a Gi coupled GPCR. Morphine, an opioid analgesic drug, acts as an agonist at 
µOR to exert pain relief in moderate to severe pain conditions. Loss of analgesic 
effectiveness of morphine following repeated use is mainly attributed to the 
desensitization of the µOR and cellular adaptations that takes place following 
stimulation of µOR. The molecular mechanisms associated with desensitization of µOR 
need further understanding. 
In order to investigate the role of PI3Kγ in µOR mediated signaling we generated 
suitable model cell systems. At first, SK-N-LO cells endogenously expressing PI3Kγ 
were transfected with a plasmid encoding µOR to generate a cell line stably expressing 
µOR (m-µOR SK-N-LO cells). Then, PI3Kγ gene was stably down regulated in m-µOR 
SK-N-LO cells using shRNA approach to generate γ5-m-µOR SK-N-LO cells with 
down-regulated PI3Kγ (~ 70 % suppression was observed) and Ctrl-m-µOR SK-N-LO 
cells expressing normal levels of PI3Kγ (shRNA control). 
Stimulation of m-µOR SK-N-LO cells with morphine resulted in activation of AKT and 
ERK1/2. Maximum activation was observed at 2.5 min post stimulation. Activation of 
AKT was evidenced by phosphorylation of AKT at serine 473 and threonine 308. 
Pertussis toxin (Gi inactivator), naloxone (specific µOR  antagonist) and wortmannin 
(pan PI3Ks inhibitor) pretreatment inhibited the morphine induced activation of AKT 
and ERK1/2 in m-µOR SK-N-LO cells, suggesting the involvement of Gi-coupled 
GPCRs, in particular µOR and a pathway dependent on activation of PI3Ks. 
Pharmacological inhibition of PI3Kβ or PI3Kγ isoform impaired the morphine induced 
activation of AKT in m-µOR SK-N-LO cells. However, pharmacological inhibition of 
PI3Kα or PI3Kδ isoform did not interfere with morphine induced activation of AKT in 
m-µOR SK-N-LO cells. Moreover, in response to morphine, γ5-m-µOR SK-N-LO 
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PI3Kγ down-regulated cells showed significantly reduced phosphorylation of AKT at 
serine 473 and threonine 308 sites indicating the requirement of PI3Kγ for the morphine 
induced activation of AKT.   
Preincubation of m-µOR SK-N-LO cells with intracellular cAMP elevating agents, 
forskolin or IBMX, inhibited the activation of AKT in response to morphine. In 
addition, inhibition of PKA by H-89 enhanced the morphine induced phosphorylation of 
AKT at threonine 308 site. Together, these data indicated a crosstalk between cAMP-
AKT pathways in m-µOR SK-N-LO cells. Further, H-89 pretreatment resulted in 
significantly reduced enhancement of morphine induced AKT activation in γ5-m-µOR 
SK-N-LO down-regulated cells compared to Ctrl-m-µOR SK-N-LO cells indicating the 
requirement of PI3Kγ for the crosstalk between cAMP-AKT pathways. 
Here we showed for the first time, morphine induced activation of AKT as measured by 
the phosphorylation of AKT at threonine 308 site. Taking this as a marker, the crosstalk 
between cAMP-AKT pathways was explored. The novel observations included the 
enhancement of morphine induced phosphorylation of AKT at threonine 308 site 
following inhibition of PKA by H-89 and its dependence on PI3Kγ. Because the 
activation of AKT might be considered as a marker for the lipid kinase activity of 
PI3Kγ, we could propose that the inhibition of PKA might have enhanced the lipid 
kinase activity of PI3Kγ, as measured by the phosphorylation of AKT at threonine 308 
site. 
Finally, the crosstalk between cAMP-AKT pathways has been explored in primary 
neuronal cells from wild type and PI3Kγ knockout mice. Morphine induced activation 
of AKT was observed in cultured DRG neurons of wild type but not PI3Kγ knockout 
mice as measured by the phosphorylation of AKT at threonine 308 site. Moreover, 
forskolin pretreatment of DRG neurons of wild type mice resulted in inhibition of 
morphine induced AKT activation which was not observed in DRG neurons from 
PI3Kγ knockout mice. Inhibition of PKA by H-89 resulted in enhanced morphine 
induced activation of AKT in wild type DRG neurons but not in PI3Kγ knockout DRG 
neurons. 
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8. Appendix  
Symbols 
o
C degree Celicus 
g Gramm 
h Hour 
kDa kilo Dalton 
min Minute 
rpm Rounds per minute 
Abbreviations 
µOR Mu-opioid receptor 
4E-BP Eucaryotic translation initiation factor 4E binding protein 1 
ABD Adapter binding domain 
ADP Adenosine diphosphate 
AKT (PKB) Protein Kinase B 
ATP Adenosine triphosphate 
cAMP Cyclic adenosine monophosphate 
DNA Deoxyribonucleic acid 
E.coli Escherichia coli 
ERK Extracellular signal-regulated Kinase 
fMLP Formyl-Methyl-Leucyl-Phenylalanin 
GAP GTPase activating proteins 
GDP Guanosine diphosphate 
GEF Guanine exchange factors 
GFP Green flourescent protein 
GPCR G-protein coupled receptor 
GRK G-protein coupled receptor kinase 
GSK3β Glycogen synthase kinase-3β 
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GTP Guanosine triphosphate 
IBMX 3-Isobutyl-1-methyxanthine 
LB Luria Broth 
MAPK Mitogen-activated protein kinase 
mRNA messenger RNA 
mTORC mammalian target of rapamycin complex 
NMDA N-methyl-D-glutamate aspartate 
NO Nitric oxide 
p70S6K p70S6K kinase 
PDE3B Phosphodiesaterase 3B 
PDK1 Phosphoinositide dependent kinase1 
PH Pleckstrin homology 
PI3K Phosphoinositide 3- kinase 
PKA Protein kinase A 
PKC Protein kinase C 
PtdIns Phosphoinositide 
PtdIns(3)P Phosphoinositide (3) Phosphate 
PtdIns(3,4,5)P3 Phosphoinositide (3,4,5) triphosphate 
PtdIns(4,5)P2 Phosphoinositide (4,5) diphosphate 
PTEN phosphatase and tensin homolog deleted on chromosome 10 
RBD RAS-binding domain 
RNAi RNA interference 
ROS Reactive oxygen species 
SH2 Src homology 2 
SH3 Src homology 3 
SHIP Src-homology (SH2)-domain containing inositol 5-phosphatase 
shRNA small hairpin RNA 
TRPV1 Transient receptor potential vanilloid receptor-1 
VGCC Voltage-gated Ca
2+ 
channels 
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